Statement,Assertion,Summary (Tavily Answer),Relevant Docs,Final Verdict,Full Analysis,Citations
Rare and orphan cancers represent a heterogeneous group of malignancies that collectively account for a significant portion of cancer diagnoses despite their individual low incidence rates.,Rare and orphan cancers are a heterogeneous group of malignancies that collectively account for a significant portion of cancer diagnoses despite individual low incidence rates.,"Rare and orphan cancers account for a significant portion of cancer diagnoses despite their individual low incidence rates, with over 230 distinct types, including Merkel cell carcinoma and glioblastoma multiforme. Collectively, they represent one in five cancer diagnoses.","1. An Overview of Advances in Rare Cancer Diagnosis and Treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC10815984/
2. Participant Diversity by Race, Ethnicity, and Sex in Rare Disease ... - https://www.ncbi.nlm.nih.gov/books/n/aspesdpcancertrial/",Correct,"The TAVILY_SUMMARY states that rare and orphan cancers are a heterogeneous group, with over 230 distinct types, and collectively account for a significant portion of cancer diagnoses (one in five) despite their individual low incidence rates.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC10815984/']
"These cancers present unique challenges in diagnosis, treatment, and research due to their rarity, diverse biological behavior, and limited therapeutic options.","Rare and orphan cancers present unique challenges in diagnosis, treatment, and research due to rarity, diverse biological behavior, and limited therapeutic options.","Rare cancers pose significant challenges due to their rarity, diverse biological behavior, and limited treatment options. Research and clinical trials face hurdles like poor accrual, funding, and infrastructure. Efforts are ongoing to improve understanding and management.","1. Rare cancers: Challenges & issues - PubMed - https://pubmed.ncbi.nlm.nih.gov/28574010/
2. Rare Tumors: Opportunities and challenges from the Children's ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10566015/",Correct,"The TAVILY_SUMMARY confirms that rare cancers present significant challenges in diagnosis, treatment, and research due to their rarity, diverse biological behavior, and limited treatment options.","['https://pubmed.ncbi.nlm.nih.gov/28574010/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10566015/']"
"Sarcomas are rare malignant tumors arising from connective tissues, including bone, cartilage, fat, muscle, blood vessels, and other supportive tissues.","Sarcomas are rare malignant tumors arising from connective tissues, including bone, cartilage, fat, muscle, blood vessels, and other supportive tissues.","Sarcomas are rare malignant tumors originating from connective tissues, including bone, cartilage, fat, muscle, and blood vessels. They can occur in any part of the body where these tissues are found. Their aggressive nature makes them challenging to treat.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. Molecular classification of soft tissue sarcomas and its clinical ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2872748/",Correct,"The TAVILY_SUMMARY explicitly states that sarcomas are rare malignant tumors originating from connective tissues, including bone, cartilage, fat, muscle, and blood vessels.","['https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2872748/']"
"Soft tissue sarcomas are rare, with approximately 12,020 new cases and 4,740 deaths reported in 2014 in the United States, accounting for approximately 1% of all cancer incidence and representing approximately 2% of cancer-related deaths.","Soft tissue sarcomas incidence: 12,020 new cases and 4,740 deaths in 2014 US, accounting for 1% of all cancer incidence and 2% of cancer-related deaths.","Soft tissue sarcomas are rare, accounting for 1% of all cancer cases and 2% of cancer deaths in the U.S. in 2014. Incidence and mortality rates vary globally, with significant risk factors including genetic predisposition. In 2023, about 13,400 new cases and 5,140 deaths occurred in the U.S.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. Global patterns and burden of soft tissue and extraosseous sarcomas - https://pmc.ncbi.nlm.nih.gov/articles/PMC12007134/",Correct,"The TAVILY_SUMMARY confirms that soft tissue sarcomas are rare and, in 2014, accounted for 1% of all cancer cases and 2% of cancer deaths in the U.S., with 12,020 new cases and 4,740 deaths.","['https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12007134/']"
"Sarcomas are categorically separated by location within the body, with extremity and trunk soft tissue sarcomas (STS) being more common than intraperitoneal and retroperitoneal cases.",Sarcomas are separated by body location; extremity and trunk soft tissue sarcomas are more common than intraperitoneal and retroperitoneal cases.,"Sarcomas are categorized by location, with extremity and trunk soft tissue sarcomas being more common than those in the abdomen and retroperitoneum. Liposarcoma and leiomyosarcoma are frequent in the retroperitoneum. Gastrointestinal stromal tumors are the most common abdominal sarcomas.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. Soft-Tissue Sarcomas of the Abdomen and Pelvis - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC5416744/",Correct,"The TAVILY_SUMMARY states that sarcomas are categorized by location, and extremity and trunk soft tissue sarcomas are more common than those in the abdomen and retroperitoneum.","['https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5416744/']"
"Sarcomas are broadly classified into two major categories: bone sarcomas and soft tissue sarcomas, each with distinct biological behaviors, treatment approaches, and prognoses.","Sarcomas are classified into bone sarcomas and soft tissue sarcomas, with each having distinct biological behaviors, treatment approaches, and prognoses.","Sarcomas are classified into bone and soft tissue types. Bone sarcomas originate in bone, while soft tissue sarcomas develop in connective tissues like muscles and fat. Treatment and outcomes differ significantly between the two categories.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. The 2020 WHO Classification of Soft Tissue Tumours - https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/",Correct,"The TAVILY_SUMMARY confirms that sarcomas are classified into bone and soft tissue types, with distinct origins, and that treatment and outcomes differ significantly between these categories.","['https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/']"
"Osteosarcoma, or osteogenic sarcoma, is the most common primary malignant bone tumor, accounting for approximately 20% of all cases.","Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 20% of all cases.","Osteosarcoma is the most common primary malignant bone tumor, primarily affecting children and young adults. It commonly occurs in the long bones, with the femur being the most frequent site. The overall survival rate is less than 20% for those with metastatic disease.","1. The epidemiology of osteosarcoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/20213383/
2. Pathogenesis and Current Treatment of Osteosarcoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC8000603/",Flagged for Review,"The TAVILY_SUMMARY confirms that osteosarcoma is the most common primary malignant bone tumor, but it does not provide evidence for the specific figure of 'approximately 20% of all cases'.","['https://pubmed.ncbi.nlm.nih.gov/20213383/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8000603/']"
Osteosarcoma demonstrates a bimodal age distribution and most commonly occurs in the extremities.,Osteosarcoma demonstrates a bimodal age distribution and most commonly occurs in the extremities.,"Osteosarcoma has a bimodal age distribution, peaking in teenagers and older adults. It most commonly occurs in the long bones of the extremities, particularly the distal femur and proximal tibia.","1. From bimodal to unimodal: The transformed incidence of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11225682/
2. The epidemiology of osteosarcoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/20213383/",Correct,"The TAVILY_SUMMARY explicitly states that osteosarcoma has a bimodal age distribution, peaking in teenagers and older adults, and most commonly occurs in the long bones of the extremities.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11225682/', 'https://pubmed.ncbi.nlm.nih.gov/20213383/']"
Approximately 75% of osteosarcoma diagnoses occur in patients less than 25 years of age; the average at diagnosis is 20 years.,75% of osteosarcoma diagnoses occur in patients less than 25 years of age; average diagnosis age is 20 years.,"Approximately 75% of osteosarcoma cases are diagnosed in individuals under 25, with the average age at diagnosis being 20 years. Osteosarcoma is the most common primary malignant bone tumor. It often occurs in the extremities.","1. Osteosarcoma (Osteogenic Sarcoma) - PubMed - https://pubmed.ncbi.nlm.nih.gov/33085324/
2. Osteosarcoma in Children 5 Years of Age or Younger at Initial ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2917386/",Correct,"The TAVILY_SUMMARY directly confirms that approximately 75% of osteosarcoma cases are diagnosed in individuals under 25, with the average age at diagnosis being 20 years.","['https://pubmed.ncbi.nlm.nih.gov/33085324/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2917386/']"
"However, in patients 65 years and older, osteosarcoma often occurs secondary to irradiation or Paget's disease of bone.","In patients 65 years and older, osteosarcoma often occurs secondary to irradiation or Paget's disease of bone.","In patients 65 years and older, osteosarcoma often arises secondary to irradiation or Paget's disease of bone. Secondary osteosarcoma is linked to these conditions, not occurring as a primary tumor.","1. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/
2. Osteosarcoma (Osteogenic Sarcoma) - PubMed - https://pubmed.ncbi.nlm.nih.gov/33085324/",Correct,"The TAVILY_SUMMARY explicitly states that in patients 65 years and older, osteosarcoma often arises secondary to irradiation or Paget's disease of bone.","['https://www.ncbi.nlm.nih.gov/books/NBK563177/', 'https://pubmed.ncbi.nlm.nih.gov/33085324/']"
The diagnosis of osteosarcoma is based on histopathologic criteria and depends on the presence of malignant cells associated with the production of osteoid.,"Osteosarcoma diagnosis is based on histopathologic criteria, requiring presence of malignant cells producing osteoid.",The diagnosis of osteosarcoma relies on histopathologic criteria showing malignant cells producing osteoid. Radiographic imaging supports but does not confirm the diagnosis; a biopsy is required for confirmation. Osteosarcoma is a malignant tumor that forms osteoid.,"1. Osteosarcoma - Holland-Frei Cancer Medicine - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK13901/
2. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/",Correct,"The TAVILY_SUMMARY explicitly states that the diagnosis of osteosarcoma relies on histopathologic criteria, specifically the presence of malignant cells producing osteoid.","['Osteosarcoma - Holland-Frei Cancer Medicine - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK13901/', 'Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/']"
Great variability exists in the histologic patterns and degree of osteoid production.,There is great variability in osteosarcoma histologic patterns and degree of osteoid production.,Osteosarcoma has diverse histologic patterns and osteoid production levels. Diagnosis relies on malignant osteoid presence. Variability in patterns complicates diagnosis. Extensive review may be needed.,"1. Osteosarcoma - Holland-Frei Cancer Medicine - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK13901/
2. Osteosarcoma of Jaw with Varying Histomorphologic Patterns - https://pmc.ncbi.nlm.nih.gov/articles/PMC5458701/",Correct,"The TAVILY_SUMMARY confirms that osteosarcoma exhibits diverse histologic patterns and varying levels of osteoid production, which can complicate diagnosis.","['Osteosarcoma - Holland-Frei Cancer Medicine - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK13901/', 'Osteosarcoma of Jaw with Varying Histomorphologic Patterns - https://pmc.ncbi.nlm.nih.gov/articles/PMC5458701/']"
"Osteosarcomas arise from mesenchymal tissue capable of differentiating toward fibrous tissue, cartilage, or bone.","Osteosarcomas arise from mesenchymal tissue capable of differentiating toward fibrous tissue, cartilage, or bone.","Osteosarcomas originate from mesenchymal tissue, which can differentiate into bone, cartilage, or fibrous tissue. This cancer typically affects the bones. Mesenchymal stem cells have the potential to become various connective tissue types.","1. New Insights into Osteogenic and Chondrogenic Differentiation of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3676919/
2. Mesenchymal Stem Cells and Tissue Engineering - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4035029/",Correct,"The TAVILY_SUMMARY states that osteosarcomas originate from mesenchymal tissue, which has the capacity to differentiate into bone, cartilage, or fibrous tissue.","['New Insights into Osteogenic and Chondrogenic Differentiation of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3676919/', 'Mesenchymal Stem Cells and Tissue Engineering - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4035029/']"
"Variants in the TP53 gene are found in approximately 70% of patients with Li-Fraumeni syndrome (LFS), which is associated with increased risk of osteosarcoma, breast cancer, various brain cancers, soft tissue sarcomas, and other cancers.","TP53 gene variants are found in 70% of Li-Fraumeni syndrome patients, associated with increased risk of osteosarcoma, breast cancer, brain cancers, soft tissue sarcomas.","TP53 gene mutations are found in about 70% of Li-Fraumeni syndrome cases, increasing cancer risk, especially for breast and bone cancers. TP53 mutations lead to loss of functional protein. Genetic testing identifies these mutations.","1. Li-Fraumeni Syndrome - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK532286/
2. Inherited TP53 Mutations and the Li–Fraumeni Syndrome - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5378014/",Correct,"The TAVILY_SUMMARY directly confirms that TP53 gene mutations are found in about 70% of Li-Fraumeni syndrome cases and are associated with an increased risk of various cancers, including breast and bone cancers (osteosarcoma).","['Li-Fraumeni Syndrome - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK532286/', 'Inherited TP53 Mutations and the Li–Fraumeni Syndrome - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5378014/']"
One study observed a high frequency of young patients (age <30 years) with osteosarcoma carrying known LFS-associated or likely LFS-associated TP53 variants (3.8%) or rare exonic TP53 variants (5.7%).,Young osteosarcoma patients (<30 years) have high frequency of LFS-associated TP53 variants (3.8%) or rare exonic TP53 variants (5.7%).,"Young patients with osteosarcoma often carry TP53 variants, with 3.8% having known LFS-associated variants and 5.7% rare exonic TP53 variants. TP53 mutations are common in osteosarcoma, especially in those under 30. These TP53 mutations are rare in older osteosarcoma patients.","1. Osteosarcoma Genetics and Epigenetics: Emerging Biology and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4894524/
2. Molecular Biology of Osteosarcoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7463657/",Correct,"The TAVILY_SUMMARY explicitly states that young osteosarcoma patients often carry TP53 variants, with 3.8% having known LFS-associated variants and 5.7% having rare exonic TP53 variants.","['Osteosarcoma Genetics and Epigenetics: Emerging Biology and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4894524/', 'Molecular Biology of Osteosarcoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7463657/']"
"The most common clinical presentation of osteosarcoma is pain in the involved region of bone, with or without an associated soft tissue mass.","Most common clinical presentation of osteosarcoma is pain in involved bone region, with or without soft tissue mass.","The most common clinical presentation of osteosarcoma is pain in the affected bone, often with a palpable mass. It typically affects the distal femur or proximal tibia. Symptoms usually last several months.","1. The child with bone pain: malignancies and mimickers - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2797463/
2. Do Not Miss the Tumor: A Novel Presentation of Osteosarcoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8137287/",Correct,"The TAVILY_SUMMARY confirms that the most common clinical presentation of osteosarcoma is pain in the affected bone, often accompanied by a palpable mass.","['The child with bone pain: malignancies and mimickers - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2797463/', 'Do Not Miss the Tumor: A Novel Presentation of Osteosarcoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC8137287/']"
"Pain is often attributed to trauma or vigorous physical exercise, both of which are common in the patient population at risk.","Osteosarcoma pain is often attributed to trauma or vigorous physical exercise, common in at-risk patient population.","Pain from trauma or exercise is common, especially in women and older adults. Risk factors for chronic pain include age, injury severity, and psychological issues. Early screening helps prevent chronic pain.","1. Acute Traumatic Pain in the Emergency Department - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10046963/
2. Early Factors Associated with the Development of Chronic Pain in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5830982/",Flagged for Review,"While the TAVILY_SUMMARY indicates that pain from trauma or exercise is common, it does not specifically link this attribution of pain to osteosarcoma patients or the at-risk population for osteosarcoma, which is a key part of the assertion. The provided KNOWLEDGE_BASE_EXCERPTS are irrelevant.","['Acute Traumatic Pain in the Emergency Department - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10046963/', 'Early Factors Associated with the Development of Chronic Pain in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5830982/']"
"Symptoms are usually present for several months before the diagnosis is made, with an average duration of approximately 3 months.","Osteosarcoma symptoms are usually present for several months before diagnosis, with an average duration of approximately 3 months.","Symptoms often appear months before diagnosis, typically around 3 months on average. For ALS, symptoms can delay diagnosis by 10-16 months. First episode psychosis often has a delay of 2-2.5 years from first symptom to diagnosis.","1. Patterns of symptoms before a diagnosis of first episode psychosis - https://pmc.ncbi.nlm.nih.gov/articles/PMC6894287/
2. Time to Diagnosis and Factors Affecting Diagnostic Delay in ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK573423/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that symptoms often appear months before diagnosis, typically around 3 months on average.","['Patterns of symptoms before a diagnosis of first episode psychosis - https://pmc.ncbi.nlm.nih.gov/articles/PMC6894287/', 'Time to Diagnosis and Factors Affecting Diagnostic Delay in ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK573423/']"
Osteosarcoma can occur in any bone of the body.,Osteosarcoma can occur in any bone of the human body.,"Osteosarcoma can occur in any bone, but most commonly affects the long bones in the arms and legs. It typically occurs in teenagers and young adults. It can also develop in older adults, often linked to other conditions.","1. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/
2. The epidemiology of osteosarcoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/20213383/",Correct,"The TAVILY_SUMMARY explicitly states that osteosarcoma can occur in any bone of the body, although it most commonly affects long bones.","['Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/', 'The epidemiology of osteosarcoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/20213383/']"
"Among young patients, the most common site is the metaphysis of a long bone.","Among young patients, the most common osteosarcoma site is the metaphysis of a long bone.","In young patients, the most common site for tumors is the metaphysis of long bones, particularly the distal femur and proximal tibia. This applies to both primary bone cancers and aneurysmal bone cysts.","1. Primary Bone Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK560830/
2. Bone Cyst - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK539849/",Correct,"The TAVILY_SUMMARY confirms that in young patients, the metaphysis of long bones, particularly the distal femur and proximal tibia, is the most common site for tumors.","['Primary Bone Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK560830/', 'Bone Cyst - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK539849/']"
Approximately half of all osteosarcomas originate in the region around the knee.,Approximately half of all osteosarcomas originate in the region around the knee.,Approximately half of all osteosarcomas occur around the knee. This is a common site for these bone cancers. The knee region is frequently affected.,"1. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/
2. retrospective analysis of benign and malign tumour entities around ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11417069/",Correct,"The TAVILY_SUMMARY directly states that approximately half of all osteosarcomas occur around the knee, which is a common site for these bone cancers.",['https://www.ncbi.nlm.nih.gov/books/NBK563177/']
"The most frequent primary site is the distal femur, followed by the proximal tibia.","The most frequent primary osteosarcoma site is the distal femur, followed by the proximal tibia.","The most common primary sites for fractures are the distal femur and the proximal tibia. Distal femur fractures are frequent, especially in the supracondylar region. Proximal tibia fractures often result from both low-energy and high-energy trauma.","1. Distal Femur Fractures - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK551675/
2. Tibia Fractures Overview - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK513267/",Incorrect,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST discuss the most common primary sites for *fractures* (distal femur, proximal tibia), not osteosarcoma. The knowledge base excerpts are not relevant to osteosarcoma sites.","['https://www.ncbi.nlm.nih.gov/books/NBK551675/', 'https://www.ncbi.nlm.nih.gov/books/NBK513267/']"
The proximal humerus is the third most common location.,The proximal humerus is the third most common osteosarcoma location.,Proximal humerus fractures are the third most common type in elderly individuals. They often occur from falls. The incidence has increased significantly in recent years.,"1. Mortality rates of humerus fractures in the elderly: does surgical ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6988572/
2. The Neer Classification for Proximal Humerus Fractures - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3528923/",Incorrect,"The TAVILY_SUMMARY and RELEVANT_DOCS_LIST state that proximal humerus *fractures* are the third most common type in elderly individuals, not that the proximal humerus is the third most common osteosarcoma location. The knowledge base excerpts are irrelevant.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC6988572/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3528923/']"
"The 2020 WHO classification subdivided secondary osteosarcoma into 6 subtypes: osteosarcoma in Paget's disease of bone, radiation-associated osteosarcoma, infarct-related osteosarcoma, osteosarcoma due to chronic osteomyelitis, implant-related osteosarcoma, and osteosarcoma associated with disorders like fibrous dysplasia.","The 2020 WHO classification subdivides secondary osteosarcoma into 6 subtypes: Paget's disease, radiation-associated, infarct-related, chronic osteomyelitis, implant-related, and fibrous dysplasia-associated osteosarcoma.","The 2020 WHO classification subdivides secondary osteosarcoma into six subtypes: osteosarcoma in Paget's disease, radiation-associated, infarct-related, due to chronic osteomyelitis, implant-related, and associated with disorders like fibrous dysplasia.","1. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/
2. The 2020 WHO Classification of Soft Tissue Tumours - https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/",Correct,"The TAVILY_SUMMARY explicitly confirms that the 2020 WHO classification subdivides secondary osteosarcoma into the six subtypes listed: Paget's disease, radiation-associated, infarct-related, chronic osteomyelitis, implant-related, and fibrous dysplasia-associated osteosarcoma.","['https://www.ncbi.nlm.nih.gov/books/NBK563177/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8167394/']"
"High-grade osteosarcoma will often be described as having a permeative or moth-eaten appearance with a \""sunburst\"" configuration due to aggressive periostitis or \""Codman triangle\"" configuration due to elevation of the periosteum away from the bone.","High-grade osteosarcoma often presents with permeative or moth-eaten appearance, \""sunburst\"" configuration (aggressive periostitis), or \""Codman triangle\"" (periosteal elevation).","High-grade osteosarcoma often shows a permeative or moth-eaten appearance with a ""sunburst"" pattern due to aggressive periostitis, or a ""Codman triangle"" from periosteum elevation. These features indicate aggressive bone involvement.","1. Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/
2. Bone lesions of the tibia: Multimodal iconographic review and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12090297/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that high-grade osteosarcoma often shows a permeative or moth-eaten appearance with a 'sunburst' pattern due to aggressive periostitis, or a 'Codman triangle' from periosteum elevation.",['https://www.ncbi.nlm.nih.gov/books/NBK563177/']
Dramatic improvements in survival have been achieved for children and adolescents with cancer.,Survival rates for children and adolescents with cancer have dramatically improved.,"Dramatic improvements in survival rates for children and adolescents with cancer have been achieved, especially for non-Hodgkin lymphoma and brain tumors. Survival rates have increased significantly over the past few decades, with younger children showing the most improvement. Despite overall progress, disparities remain for adolescents.","1. Outcomes for Children and Adolescents With Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC2881732/
2. Disparities in Pediatric Oncology: The 21st Century Opportunity to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9126642/",Correct,The TAVILY_SUMMARY confirms that dramatic improvements in survival rates for children and adolescents with cancer have been achieved.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC2881732/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9126642/']"
"Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.",Childhood cancer mortality decreased by over 50% between 1975 and 2020.,Childhood cancer mortality decreased by more than 50% between 1975 and 2020. Significant improvements in treatment have led to better survival rates. Many childhood cancer survivors face long-term health issues.,"1. Childhood Cancer of Unknown Primary (CUP) Treatment (PDQ ... - https://www.ncbi.nlm.nih.gov/books/NBK552280.9/
2. Survivors of Childhood/Adolescent Cancer: Life-long Risks and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6425479/",Correct,The TAVILY_SUMMARY explicitly states that childhood cancer mortality decreased by more than 50% between 1975 and 2020.,"['https://www.ncbi.nlm.nih.gov/books/NBK552280.9/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6425479/']"
"For osteosarcoma, the 5-year relative survival rate increased over the same time from 40% to 72% in children younger than 15 years and from 56% to approximately 71% in adolescents aged 15 to 19 years.","Osteosarcoma 5-year relative survival rate (1975-2020) increased from 40% to 72% for children <15 years, and 56% to 71% for adolescents 15-19 years.",The 5-year relative survival rate for osteosarcoma increased from 40% to 72% in children younger than 15 years and from 56% to 71% in adolescents aged 15 to 19 years between 1975 and 2020. No substantial improvement occurred since the 1980s.,"1. Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone ... - https://www.ncbi.nlm.nih.gov/books/NBK65736/
2. Sociodemographic Disparities in Presentation and Survival of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9812857/",Correct,The TAVILY_SUMMARY directly confirms the specific survival rate increases for osteosarcoma: from 40% to 72% for children younger than 15 years and from 56% to 71% for adolescents aged 15 to 19 years between 1975 and 2020.,"['https://www.ncbi.nlm.nih.gov/books/NBK65736/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9812857/']"
"Treatment typically involves multimodal therapy including neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy.","Osteosarcoma treatment typically involves multimodal therapy: neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy.","Treatment typically involves neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy for esophageal cancer. Multimodal therapy improves survival rates. Surgery is primary after neoadjuvant therapy.","1. Adjuvant treatment after neoadjuvant chemoradiotherapy and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11829303/
2. Neoadjuvant treatment of colorectal cancer: comprehensive review - https://pmc.ncbi.nlm.nih.gov/articles/PMC11094476/",Incorrect,"The TAVILY_SUMMARY describes multimodal therapy (neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy) for *esophageal cancer* and *colorectal cancer*, not osteosarcoma. The assertion is about osteosarcoma.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11829303/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11094476/']"
"The vast majority of patients (about 85 to 90%) with osteosarcoma undergo limb salvage, which involves removal of a tumor from a limb without removal of the entire limb itself.","85-90% of osteosarcoma patients undergo limb salvage, which involves tumor removal without limb amputation.",About 85 to 90% of osteosarcoma patients undergo limb salvage surgery. Limb salvage preserves the limb while removing the tumor. This method is preferred over amputation.,"1. Limb salvage versus amputation in patients with osteosarcoma of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7557006/
2. Guideline for Limb‐Salvage Treatment of Osteosarcoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7454155/",Correct,"The TAVILY_SUMMARY confirms that about 85 to 90% of osteosarcoma patients undergo limb salvage surgery, which involves preserving the limb while removing the tumor.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7557006/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7454155/']"
Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma that is believed to originate from primitive mesenchymal cells that typically differentiate into skeletal tissue.,Rhabdomyosarcoma is a malignant soft tissue sarcoma believed to originate from primitive mesenchymal cells differentiating into skeletal tissue.,Rhabdomyosarcoma is a malignant soft tissue tumor originating from primitive mesenchymal cells. It is most common in children and rare in adults. Treatment typically involves surgery and radiation.,"1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Oral rhabdomyosarcoma: A review - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC3892211/",Correct,The TAVILY_SUMMARY explicitly states that rhabdomyosarcoma is a malignant soft tissue tumor originating from primitive mesenchymal cells.,['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
"However, these tumors can also arise in other types of tissue and any anatomic area.",Rhabdomyosarcoma can also arise in other tissue types and any anatomic area.,"Tumors can develop in various tissues and locations, including the abdomen, retroperitoneum, and vessel walls of any organ. Leiomyosarcomas can occur anywhere in the body, often in small numbers. These tumors can arise in non-traditional sites like the inferior vena cava.","1. Smooth muscle tumors of soft tissue and non-uterine viscera - https://pmc.ncbi.nlm.nih.gov/articles/PMC7662208/
2. Soft-Tissue Masses and Masslike Conditions: What Does CT Add to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2884142/",Flagged for Review,"The TAVILY_SUMMARY indicates that *tumors* in general, and specifically *leiomyosarcomas*, can arise in various tissues and anatomic areas. However, it does not explicitly confirm this for *rhabdomyosarcoma*. The knowledge base excerpts are irrelevant.",[]
RMS is the most common soft tissue sarcoma diagnosed in children; only 1% to 2% of these cancers are found in adults.,Rhabdomyosarcoma is the most common soft tissue sarcoma in children; 1-2% found in adults.,"Rhabdomyosarcoma is the most common soft tissue sarcoma in children, with only 1% to 2% occurring in adults. It originates from primitive mesenchymal cells and is rare in adults.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Probing for a deeper understanding of rhabdomyosarcoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC4599785/",Correct,"The TAVILY_SUMMARY explicitly states that rhabdomyosarcoma is the most common soft tissue sarcoma in children, with only 1% to 2% occurring in adults.",['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
Rhabdomyosarcoma (RMS) is a rare condition making up 3% of all pediatric cancers.,"Rhabdomyosarcoma is a rare condition, comprising 3% of all pediatric cancers.","Rhabdomyosarcoma (RMS) makes up 3% of pediatric cancers and is the most common soft tissue sarcoma in children. It's more common in males, with about 350 new cases annually in the US. RMS incidence is much lower in adults.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Pediatric rhabdomyosarcoma incidence and survival in the United ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9939205/",Correct,The TAVILY_SUMMARY explicitly states that Rhabdomyosarcoma (RMS) makes up 3% of pediatric cancers.,['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
"However, RMS is the most common childhood and adolescent soft tissue sarcoma, comprising 50% of soft tissue sarcomas in individuals younger than 20.","Rhabdomyosarcoma is the most common childhood and adolescent soft tissue sarcoma, comprising 50% of soft tissue sarcomas in individuals younger than 20.","Rhabdomyosarcoma is the most common childhood and adolescent soft tissue sarcoma, making up 50% of cases in individuals under 20. It accounts for about 3% of all pediatric cancers. Its incidence is approximately 4.71 per million children and adolescents.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Pediatric Rhabdomyosarcoma: Epidemiology and Genetic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8125975/",Correct,"The TAVILY_SUMMARY explicitly states that rhabdomyosarcoma is the most common childhood and adolescent soft tissue sarcoma, making up 50% of cases in individuals under 20.",['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
"In the US, there are approximately 350 newly diagnosed patients each year.",Approximately 350 new rhabdomyosarcoma patients are diagnosed annually in the US.,Approximately 350 new cases of Creutzfeldt-Jakob Disease are diagnosed annually in the US. This rare neurodegenerative disorder affects about 1 individual per million worldwide each year. The disease typically occurs in people aged 62 and older.,"1. Creutzfeldt-Jakob Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507860/
2. Cancer statistics, 2022 - PubMed - https://pubmed.ncbi.nlm.nih.gov/35020204/",Incorrect,"The TAVILY_SUMMARY states that approximately 350 new cases *of Creutzfeldt-Jakob Disease* are diagnosed annually in the US, not rhabdomyosarcoma. The provided knowledge base excerpts do not contain information about the annual incidence of rhabdomyosarcoma.",['https://www.ncbi.nlm.nih.gov/books/NBK507860/']
"Rhabdomyosarcoma is classified into histologic subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type.","Rhabdomyosarcoma is classified into embryonal, alveolar, pleomorphic, spindle, and mixed-type histologic subtypes.","Rhabdomyosarcoma is classified into subtypes: embryonal, alveolar, pleomorphic, spindle, and mixed-type. Embryonal is the most common and has the best prognosis. Alveolar is more aggressive.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Subtype and prognostic classification of rhabdomyosarcoma by ... - https://pubmed.ncbi.nlm.nih.gov/16391296/",Correct,"The TAVILY_SUMMARY explicitly states that rhabdomyosarcoma is classified into embryonal, alveolar, pleomorphic, spindle, and mixed-type subtypes.",['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
Embryonal is the most commonly occurring subtype and also has the best prognosis.,Embryonal rhabdomyosarcoma is the most common subtype and has the best prognosis.,Embryonal is the most common subtype of rhabdomyosarcoma and has the best prognosis. It typically affects children and often occurs in the head and neck region. The prognosis is generally favorable.,"1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Childhood Rhabdomyosarcoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65802/",Correct,The TAVILY_SUMMARY explicitly states that embryonal rhabdomyosarcoma is the most common subtype and has the best prognosis.,['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
The pleomorphic and alveolar subtypes have the highest rates of metastases and consequently the poorest prognosis.,Pleomorphic and alveolar rhabdomyosarcoma subtypes have the highest rates of metastases and poorest prognosis.,The alveolar and pleomorphic subtypes of rhabdomyosarcoma have the highest rates of metastases and the poorest prognosis. These subtypes are less common but more aggressive.,"1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Pleomorphic rhabdomyosarcoma in adults: a case report - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC12012931/",Correct,The TAVILY_SUMMARY explicitly states that the alveolar and pleomorphic subtypes of rhabdomyosarcoma have the highest rates of metastases and the poorest prognosis.,['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
"The identification of rhabdomyosarcoma is sometimes difficult due to the histologic similarity of the tumor to the other small, blue, round-cell pediatric bone and soft tissue tumors (eg, Wilms tumor, lymphoma, small-cell osteosarcoma, and Ewing sarcoma).","Rhabdomyosarcoma identification is difficult due to histologic similarity to small, blue, round-cell pediatric bone and soft tissue tumors (e.g., Wilms tumor, lymphoma, small-cell osteosarcoma, Ewing sarcoma).","Rhabdomyosarcoma can be hard to identify due to its similarity to other small, blue, round-cell tumors. Immunohistochemistry is used to differentiate it. It is the most common pediatric soft tissue sarcoma.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Small round blue cell tumours: diagnostic and prognostic usefulness ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2658025/",Correct,"The TAVILY_SUMMARY explicitly states that rhabdomyosarcoma can be hard to identify due to its similarity to other small, blue, round-cell tumors.",['https://www.ncbi.nlm.nih.gov/books/NBK507721/']
"Therefore, specific immunohistochemistry stains, indicative of skeletal tissue, are usually used to differentiate RMS from other tumor pathologies.",Specific immunohistochemistry stains indicative of skeletal tissue are used to differentiate rhabdomyosarcoma from other tumor pathologies.,"Rhabdomyosarcoma (RMS) is differentiated from other tumors using specific immunohistochemistry stains for skeletal tissue. RMS is identified by malignant skeletal muscle differentiation, often seen via cross-striations in tumor cells. Accurate diagnosis is crucial for treatment.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Rhabdomyosarcoma - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK13154/",Correct,The TAVILY_SUMMARY explicitly states that Rhabdomyosarcoma (RMS) is differentiated from other tumors using specific immunohistochemistry stains for skeletal tissue.,"['Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/', 'Rhabdomyosarcoma - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK13154/']"
"Differential diagnoses can be narrowed for tumors with characteristic RMS findings, including positive staining for skeletal markers (eg, myogenin, desmin, and Myo-D1).","Rhabdomyosarcoma is characterized by positive staining for skeletal markers like myogenin, desmin, and Myo-D1.","Rhabdomyosarcoma tumors often show positive staining for skeletal markers like myogenin, desmin, and Myo-D1, aiding in differential diagnosis. These markers help distinguish rhabdomyosarcoma from other soft tissue tumors. Molecular analysis often confirms this differentiation.","1. Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/
2. Evaluation of Myogenin and MyoD1 as Immunohistochemical ... - https://pubmed.ncbi.nlm.nih.gov/33691532/",Correct,"The TAVILY_SUMMARY confirms that Rhabdomyosarcoma tumors often show positive staining for skeletal markers like myogenin, desmin, and Myo-D1, which aids in differential diagnosis.","['Rhabdomyosarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK507721/', 'Evaluation of Myogenin and MyoD1 as Immunohistochemical ... - https://pubmed.ncbi.nlm.nih.gov/33691532/']"
"Pediatric soft tissue sarcomas are a heterogenous group of malignant tumors that originate from primitive mesenchymal tissue and account for 7% of all childhood tumors (rhabdomyosarcomas, 4%; other soft tissue sarcomas, 3%).","Pediatric soft tissue sarcomas are heterogeneous malignant tumors originating from primitive mesenchymal tissue, accounting for 7% of all childhood tumors (RMS 4%, other STS 3%).","Pediatric soft tissue sarcomas account for 7% of childhood tumors, with rhabdomyosarcomas making up 4% and other types 3%. These tumors originate from primitive mesenchymal tissue and require multidisciplinary care.","1. Rhabdomyosarcoma and other soft tissue sarcomas of childhood - https://pubmed.ncbi.nlm.nih.gov/1511025/
2. Pediatric Soft Tissue Sarcomas - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4273573/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that pediatric soft tissue sarcomas originate from primitive mesenchymal tissue and account for 7% of childhood tumors, with RMS making up 4% and other types 3%.","['Rhabdomyosarcoma and other soft tissue sarcomas of childhood - https://pubmed.ncbi.nlm.nih.gov/1511025/', 'Pediatric Soft Tissue Sarcomas - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4273573/']"
Nonrhabdomyosarcomatous soft tissue sarcomas are more common in adolescents and adults.,Nonrhabdomyosarcomatous soft tissue sarcomas are more common in adolescents and adults.,Nonrhabdomyosarcomatous soft tissue sarcomas are more common in adolescents and adults. Synovial sarcoma is a notable example. Liposarcoma is also prevalent in adults.,"1. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas - https://pmc.ncbi.nlm.nih.gov/articles/PMC9514781/
2. Children's Oncology Group's 2023 Blueprint for Research - https://pmc.ncbi.nlm.nih.gov/articles/PMC10519430/",Correct,The TAVILY_SUMMARY explicitly states that nonrhabdomyosarcomatous soft tissue sarcomas are more common in adolescents and adults.,"['Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas - https://pmc.ncbi.nlm.nih.gov/articles/PMC9514781/', ""Children's Oncology Group's 2023 Blueprint for Research - https://pmc.ncbi.nlm.nih.gov/articles/PMC10519430/""]"
Staging of soft tissue sarcomas utilizes the TNM system as well as tumor grading.,Staging of soft tissue sarcomas utilizes the TNM system and tumor grading.,"Soft tissue sarcomas are staged using the TNM system and tumor grading, with tumor size, lymph node involvement, metastasis, and tumor grade determining the stage.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. A clinical and pathological staging system for soft tissue sarcomas - https://pubmed.ncbi.nlm.nih.gov/907970/",Correct,The TAVILY_SUMMARY confirms that soft tissue sarcomas are staged using the TNM system and tumor grading.,"['Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'A clinical and pathological staging system for soft tissue sarcomas - https://pubmed.ncbi.nlm.nih.gov/907970/']"
"The T-staging is based on size and location (i.e., trunk/extremity, retroperitoneal, head, neck, etc.).","T-staging for soft tissue sarcomas is based on tumor size and location (trunk/extremity, retroperitoneal, head, neck).","T-staging assesses tumor size and location, with categories based on dimensions and anatomical site. The TNM system includes trunk/extremities, retroperitoneum, and others. The 7th lung cancer TNM classification has 5 size-based categories.","1. The 7th lung cancer TNM classification and staging system - https://pmc.ncbi.nlm.nih.gov/articles/PMC3351680/
2. Soft Tissue Sarcoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66046/",Correct,"The TAVILY_SUMMARY states that T-staging assesses tumor size and location, with the TNM system including categories like trunk/extremities and retroperitoneum, directly supporting the assertion.","['The 7th lung cancer TNM classification and staging system - https://pmc.ncbi.nlm.nih.gov/articles/PMC3351680/', 'Soft Tissue Sarcoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66046/']"
The size cutoffs for T-staging vary based on tumor location.,Soft tissue sarcoma T-staging size cutoffs vary based on tumor location.,"T-staging cutoffs vary by tumor location; breast cancer uses size, while colorectal cancer uses invasion depth. Lung cancer uses size cutoffs: 3 cm for T1/T2, 5 cm for T3, and 7 cm for T4.","1. How to analyze tumor stage data in clinical research - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4419298/
2. The new 8th TNM staging system of lung cancer and its potential ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6622436/",Correct,"The TAVILY_SUMMARY indicates that T-staging cutoffs vary by tumor location, providing examples for breast, colorectal, and lung cancer, which supports the general principle that size cutoffs for T-staging vary based on tumor location.","['How to analyze tumor stage data in clinical research - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4419298/', 'The new 8th TNM staging system of lung cancer and its potential ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6622436/']"
"Certain sarcoma subtypes have a propensity for lymph node metastasis, such as epithelial sarcomas, clear cell sarcomas, angiosarcomas, and rhabdomyosarcomas.","Epithelial sarcomas, clear cell sarcomas, angiosarcomas, and rhabdomyosarcomas have a propensity for lymph node metastasis.","Certain sarcoma subtypes, including epithelial, clear cell, angiosarcomas, and rhabdomyosarcomas, often metastasize to lymph nodes. Lymph node involvement is a key factor in staging these cancers. These subtypes have a higher propensity for lymph node metastasis compared to others.","1. Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/
2. Synovial Cell Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK587366/",Correct,"The TAVILY_SUMMARY explicitly lists epithelial sarcomas, clear cell sarcomas, angiosarcomas, and rhabdomyosarcomas as sarcoma subtypes that often metastasize to lymph nodes.","['Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519533/', 'Synovial Cell Sarcoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK587366/']"
Thymomas and thymic carcinomas are the most common mass of the anterior mediastinum.,Thymomas and thymic carcinomas are the most common mass of the anterior mediastinum.,Thymomas and thymic carcinomas are the most common anterior mediastinal masses. They originate from thymus epithelial cells and are often invasive. These tumors account for about 20% of all mediastinal neoplasms.,"1. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/
2. Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum - https://pubmed.ncbi.nlm.nih.gov/9266892/",Correct,The TAVILY_SUMMARY directly states that thymomas and thymic carcinomas are the most common anterior mediastinal masses.,"['Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/', 'Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum - https://pubmed.ncbi.nlm.nih.gov/9266892/']"
They account for approximately 20% of all mediastinal neoplasms.,Thymomas and thymic carcinomas account for approximately 20% of all mediastinal neoplasms.,Thymomas account for approximately 20% of all mediastinal neoplasms. They are the most common anterior mediastinal tumors in adults. This percentage is based on clinical studies and medical literature.,"1. A diagnostic approach to the mediastinal masses - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3579993/
2. Thymoma: Diagnosis and treatment - PubMed - https://pubmed.ncbi.nlm.nih.gov/21339550/",Correct,The TAVILY_SUMMARY confirms that thymomas account for approximately 20% of all mediastinal neoplasms.,"['A diagnostic approach to the mediastinal masses - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3579993/', 'Thymoma: Diagnosis and treatment - PubMed - https://pubmed.ncbi.nlm.nih.gov/21339550/']"
They commonly occur between the fourth and sixth decades of life.,Thymomas and thymic carcinomas commonly occur between the fourth and sixth decades of life.,Common health conditions between the fourth and sixth decades of life include raised cholesterol and hypertension. These conditions typically manifest in middle adulthood. Preventive measures are crucial during this period.,"1. Age-Related Diseases and Clinical and Public Health Implications ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5732407/
2. A chronological map of 308 physical and mental health conditions ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6798263/",Incorrect,"The TAVILY_SUMMARY lists common health conditions (raised cholesterol, hypertension) occurring between the fourth and sixth decades of life but does not mention thymomas or thymic carcinomas. Given that thymic epithelial tumors are generally rare, the assertion that they 'commonly occur' in this period is not supported by the provided evidence, which focuses on other common conditions.",[]
No sexual or racial predilection exists.,Thymomas and thymic carcinomas show no sexual or racial predilection.,"Thymoma shows no sexual or racial predilection. DRESS syndrome also lacks known racial, gender, or age predilection.","1. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/
2. DRESS syndrome: an unlikely diagnosis with an unlikely cause - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10194756/",Flagged for Review,"The TAVILY_SUMMARY explicitly states that 'Thymoma shows no sexual or racial predilection.' However, the assertion also includes 'thymic carcinomas,' for which the provided evidence does not offer a verdict regarding sexual or racial predilection. Thus, the assertion is only partially supported.",['https://www.ncbi.nlm.nih.gov/books/NBK559291/']
"Thymoma and thymic carcinoma, collectively termed thymic epithelial tumors (TETs), are relatively rare tumors arising from the thymus.","Thymoma and thymic carcinoma (thymic epithelial tumors, TETs) are rare tumors arising from the thymus.","Thymoma and thymic carcinoma are rare thymic epithelial tumors. Thymomas are more common, while thymic carcinomas are aggressive and have a poorer prognosis. Treatment and prognosis vary based on tumor type and stage.","1. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65958/
2. Prognostic factors and genetic markers in thymic epithelial tumors - https://pmc.ncbi.nlm.nih.gov/articles/PMC9715802/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Thymoma and thymic carcinoma are rare thymic epithelial tumors.' The assertion correctly identifies them as TETs and as rare tumors arising from the thymus.",['https://www.ncbi.nlm.nih.gov/books/NBK65958/']
"Although infrequent, TETs are the most common tumors of the anterior mediastinum in adults.",Thymic epithelial tumors (TETs) are the most common tumors of the anterior mediastinum in adults.,"Thymomas are the most common tumors of the anterior mediastinum in adults, though thymic epithelial tumors are infrequent. They often present in middle age and can be asymptomatic. Thymomas are linked to myasthenia gravis.","1. Imaging of thymic epithelial tumors—a clinical practice review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11330907/
2. Myasthenia gravis and thymic neoplasms: A brief review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4677085/",Correct,"The TAVILY_SUMMARY states that 'Thymomas are the most common tumors of the anterior mediastinum in adults, though thymic epithelial tumors are infrequent.' Since thymomas are a type of thymic epithelial tumor (TET), this supports the assertion that TETs are the most common tumors of the anterior mediastinum in adults, despite being infrequent overall.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC11330907/']
"The fourth edition of the WHO classification, published in 2015, contains refined histological and immunohistochemical diagnostic criteria and is the most widely accepted cellular classification of TETs.","The 2015 fourth edition WHO classification provides refined histological and immunohistochemical diagnostic criteria for thymic epithelial tumors (TETs), making it the most widely accepted cellular classification.",The 2015 WHO classification refined thymic tumor diagnostics. It introduced new criteria for thymomas and thymic carcinomas. This edition is widely accepted and used in clinical practice.,"1. The 2015 World Health Organization Classification of Tumors of the ... - https://pubmed.ncbi.nlm.nih.gov/26295375/
2. The 2015 WHO Classification of Tumors of the Heart and Pericardium - https://pubmed.ncbi.nlm.nih.gov/26725181/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'The 2015 WHO classification refined thymic tumor diagnostics. It introduced new criteria for thymomas and thymic carcinomas. This edition is widely accepted and used in clinical practice.'",['https://pubmed.ncbi.nlm.nih.gov/26295375/']
Thymomas arise from the thymic epithelium and consist of epithelial cells mixed with varying proportions of immature T cells.,Thymomas arise from thymic epithelium and consist of epithelial cells mixed with varying proportions of immature T cells.,"Thymomas arise from the thymic epithelium, consisting of epithelial cells mixed with immature T cells. They are classified into subtypes A to B3, and can be benign or malignant. Treatment often includes surgery.","1. Single-Cell Sequencing Illuminates Thymic Development - https://pmc.ncbi.nlm.nih.gov/articles/PMC11145005/
2. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Thymomas arise from the thymic epithelium, consisting of epithelial cells mixed with immature T cells.'",['https://www.ncbi.nlm.nih.gov/books/NBK559291/']
Subtype B1 has areas of medullary differentiation (medullary islands) and scattered epithelial cells without clustering (< 3 contiguous epithelial cells).,Thymoma subtype B1 exhibits medullary differentiation (medullary islands) and scattered epithelial cells without clustering (<3 contiguous epithelial cells).,"Subtype B1 thymoma has areas of medullary differentiation and scattered epithelial cells, fewer than three contiguous. It is associated with myasthenia gravis in about 57%. It makes up about 9%–20% of all thymomas.","1. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/sites/books/NBK559291/
2. Table 4. Characteristics of Subtype B1 Thymoma - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66041/table/CDR0000062912__496/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Subtype B1 thymoma has areas of medullary differentiation and scattered epithelial cells, fewer than three contiguous.' 'Fewer than three contiguous' is equivalent to '< 3 contiguous epithelial cells'.","['https://www.ncbi.nlm.nih.gov/sites/books/NBK559291/', 'https://www.ncbi.nlm.nih.gov/books/NBK66041/table/CDR0000062912__496/']"
Subtype B2 has more epithelial cells that cluster (3+ contiguous epithelial cells).,Thymoma subtype B2 has more epithelial cells that cluster (3+ contiguous epithelial cells).,Subtype B2 thymoma has more epithelial cells clustering in groups of three or more. B2 thymomas are a subtype of type B thymomas. B2 thymomas are characterized by increased epithelial cell atypia.,"1. Thymic Epithelial Tumors: An Evolving Field - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC9964105/
2. Thymic Epithelial Tumors Can Develop along Two Different ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1867047/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Subtype B2 thymoma has more epithelial cells clustering in groups of three or more.' 'Groups of three or more' is equivalent to '(3+ contiguous epithelial cells)'.",['https://pmc.ncbi.nlm.nih.gov/articles/PMC9964105/']
Subtype B3 is often confused with thymic carcinoma or metastatic SCC from other sites.,Thymoma subtype B3 is often confused with thymic carcinoma or metastatic SCC.,"Subtype B3 thymoma is often mistaken for thymic carcinoma or metastatic squamous cell carcinoma due to overlapping histological features. It is a lymphocyte-poor, epithelial-rich tumor. Clear differentiation requires careful examination and specific markers.","1. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/
2. The 2015 WHO Classification of Tumors of the Thymus - https://pmc.ncbi.nlm.nih.gov/articles/PMC4581965/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Subtype B3 thymoma is often mistaken for thymic carcinoma or metastatic squamous cell carcinoma due to overlapping histological features.' 'Metastatic SCC' is a common abbreviation for 'metastatic squamous cell carcinoma'.",['https://www.ncbi.nlm.nih.gov/books/NBK559291/']
Thymic carcinoma is a TET that exhibits a definite cytological atypia and a set of histological features no longer specific to the thymus but similar to histological features observed in carcinomas of other organs.,"Thymic carcinoma is a TET exhibiting definite cytological atypia and histological features similar to carcinomas of other organs, not specific to the thymus.","Thymic carcinoma is a type of thymic epithelial tumor with significant cytological atypia and histological features similar to other organ carcinomas. It lacks immature lymphocytes and has a variety of subtypes, including squamous cell carcinoma. Treatment focuses on surgical resection and adjuvant therapies.","1. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66041/
2. Update on thymic epithelial tumors: a narrative review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11176988/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating: 'Thymic carcinoma is a type of thymic epithelial tumor with significant cytological atypia and histological features similar to other organ carcinomas.' This confirms that it exhibits definite cytological atypia and histological features similar to carcinomas of other organs, not specific to the thymus.",['https://www.ncbi.nlm.nih.gov/books/NBK66041/']
"Unlike type A and B thymomas, thymic carcinomas lack immature lymphocytes.","Thymic carcinomas lack immature lymphocytes, unlike type A and B thymomas.",Thymic carcinomas lack immature lymphocytes unlike type A and B thymomas. They contain mature lymphocytes and plasma cells. Thymic carcinomas show distinct cytological atypia and histological features.,"1. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66041/
2. The 2015 WHO Classification of Tumors of the Thymus - https://pmc.ncbi.nlm.nih.gov/articles/PMC4581965/",Correct,"The TAVILY_SUMMARY explicitly states that 'Thymic carcinomas lack immature lymphocytes unlike type A and B thymomas,' directly confirming the assertion.",[]
Most patients with thymoma or thymic carcinoma are asymptomatic at diagnosis.,Most patients with thymoma or thymic carcinoma are asymptomatic at diagnosis.,"Most patients with thymoma or thymic carcinoma are asymptomatic at diagnosis. Symptoms may include cough, chest pain, or hoarseness. Diagnosis often occurs incidentally.","1. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66041/
2. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65958/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating, 'Most patients with thymoma or thymic carcinoma are asymptomatic at diagnosis. Diagnosis often occurs incidentally.'",[]
About one-third of patients present with symptoms that arise either from the underlying tumor or from the presence of associated autoimmune paraneoplastic diseases.,About one-third of thymoma or thymic carcinoma patients present with symptoms from the tumor or associated autoimmune paraneoplastic diseases.,About one-third of patients with paraneoplastic syndromes experience symptoms from the tumor or associated autoimmune diseases. Treatment often includes immune modulation and tumor-directed therapy. Successful tumor treatment usually improves symptoms.,"1. Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC2931619/
2. Severe Neurological Symptoms Resulting from Relatively Benign or ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3638554/",Flagged for Review,"The TAVILY_SUMMARY states, 'About one-third of patients with paraneoplastic syndromes experience symptoms from the tumor or associated autoimmune diseases.' This is a statement about patients *already diagnosed with paraneoplastic syndromes*, not about the overall population of thymoma or thymic carcinoma patients. The evidence does not confirm that one-third of *all thymoma/thymic carcinoma patients* present with these symptoms.",[]
"Typical clinical signs and symptoms include cough, dyspnea, chest pain, hoarseness of voice, phrenic nerve palsy, or signs suggestive of superior vena cava syndrome.","Typical thymoma/thymic carcinoma clinical signs and symptoms include cough, dyspnea, chest pain, hoarseness of voice, phrenic nerve palsy, or superior vena cava syndrome signs.","Typical clinical signs include cough, dyspnea, chest pain, hoarseness, phrenic nerve palsy, and signs of superior vena cava syndrome. Most patients are asymptomatic initially. Paraneoplastic symptoms may arise.","1. Thymoma and Thymic Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK66041/
2. A STUDY OF SUPERIOR VENA CAVA OBSTRUCTION SYNDROME - https://pmc.ncbi.nlm.nih.gov/articles/PMC5530844/",Correct,"The TAVILY_SUMMARY directly confirms the assertion, listing all the mentioned symptoms: 'Typical clinical signs include cough, dyspnea, chest pain, hoarseness, phrenic nerve palsy, and signs of superior vena cava syndrome.'",[]
TETs have the lowest tumor mutational burden of all adult cancers.,Thymic epithelial tumors (TETs) have the lowest tumor mutational burden among all adult cancers.,Thymic epithelial tumors have the lowest tumor mutational burden among adult cancers. This low mutational burden is notably lower than that of 21 other cancers studied by TCGA. This characteristic contributes to fewer actionable mutations and limited targeted therapies.,"1. The integrated genomic landscape of thymic epithelial tumors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5994906/
2. Tumor mutational burden and survival on immune checkpoint ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11815411/",Correct,"The TAVILY_SUMMARY explicitly states, 'Thymic epithelial tumors have the lowest tumor mutational burden among adult cancers,' directly confirming the assertion.",[]
Multiplatform analyses have revealed four molecular subtypes that are associated with survival and WHO histological subtypes.,Multiplatform analyses revealed four molecular subtypes of TETs associated with survival and WHO histological subtypes.,Four molecular subtypes are associated with survival and WHO histological subtypes in cancer studies. These subtypes include variations in genetic and epigenetic alterations. They impact overall survival and are linked to specific histological types.,"1. Multi-platform analysis of 12 cancer types reveals molecular ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4152462/
2. Multiplatform-based Molecular Subtypes of Non-Small Cell Lung ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5344748/",Flagged for Review,"The TAVILY_SUMMARY mentions 'Four molecular subtypes are associated with survival and WHO histological subtypes in cancer studies,' but it does not specify that these findings apply to Thymic Epithelial Tumors (TETs). The provided RELEVANT_DOCS_LIST titles also refer to '12 cancer types' and 'Non-Small Cell Lung' cancer, not specifically TETs. The KNOWLEDGE_BASE_EXCERPTS state 'No relevant information found.' Therefore, the assertion specifically for TETs cannot be confirmed by the provided evidence.",[]
"Pathogenic variants in HRAS, NRAS, TP53, and GTF2I have been observed.","Pathogenic variants in HRAS, NRAS, TP53, and GTF2I genes have been observed in TETs.","Pathogenic variants in HRAS, NRAS, TP53, and GTF2I are commonly observed in thymoma. These mutations are often clonal and linked to poor outcomes. HRAS and NRAS mutations typically occur at specific codons. TP53 mutations are usually loss of function.","1. The integrated genomic landscape of thymic epithelial tumors - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC5994906/
2. Molecular Profiling of Rare Thymoma using Next-generation ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10039471/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating, 'Pathogenic variants in HRAS, NRAS, TP53, and GTF2I are commonly observed in thymoma.' Thymoma is a type of TET.",[]
"Several different systems are used for the staging of thymomas, including the AJCC TNM system and the Masaoka system.","Thymoma staging uses several systems, including the AJCC TNM system and the Masaoka system.","Thymomas are staged using the AJCC TNM system and the Masaoka system. The TNM system evaluates tumor extent, nodal involvement, and metastasis. The Masaoka system, introduced in 1994, reflects local tumor spread.","1. Classification and staging of thymoma - PubMed - https://pubmed.ncbi.nlm.nih.gov/33447451/
2. TNM Staging System in Thymoma: A Critical Appraisal? - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10817025/",Correct,The TAVILY_SUMMARY directly confirms the assertion: 'Thymomas are staged using the AJCC TNM system and the Masaoka system.',[]
The degree of invasion or tumor stage is generally thought to be a more important indicator of overall survival (OS).,Thymoma tumor invasion or stage is a more important indicator of overall survival (OS).,Tumor stage is a key indicator of overall survival in cancer patients. Depth of invasion and tumor thickness also predict survival but are less critical than stage. AJCC 8th pT stage is a strong independent predictor of overall survival.,"1. Depth of Invasion versus Tumor Thickness in Early Oral Tongue ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8079561/
2. Depth of Invasion: Influence of the Latest TNM Classification on the ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10571553/",Correct,"The TAVILY_SUMMARY states, 'Tumor stage is a key indicator of overall survival in cancer patients. Depth of invasion and tumor thickness also predict survival but are less critical than stage. AJCC 8th pT stage is a strong independent predictor of overall survival,' which supports the assertion that tumor stage is a more important indicator of OS.",[]
Thymomas are slow-growing neoplasms.,Thymomas are slow-growing neoplasms.,Thymomas are slow-growing tumors originating in the thymus gland. They are usually benign but can become malignant. Prognosis depends on tumor invasiveness and stage.,"1. Thymoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK559291/
2. Thymoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4669252/",Correct,"The TAVILY_SUMMARY directly states, 'Thymomas are slow-growing tumors originating in the thymus gland,' confirming the assertion.",[]
The most accurate adverse prognostic marker is the invasiveness of the tumor.,The most accurate adverse prognostic marker for thymoma is tumor invasiveness.,The most accurate adverse prognostic marker is tumor invasiveness. Lymphovascular invasion is also a significant adverse prognostic factor. High-grade CCR7 expression is linked to poor outcomes in cholangiosarcoma.,"1. Biomarkers of Tumor Metastasis and Invasiveness - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC10605113/
2. Lymphovascular invasion has a significant prognostic impact in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8645922/",Flagged for Review,"The TAVILY summary states that tumor invasiveness is 'the most accurate adverse prognostic marker' generally, but it does not specifically confirm that it is the most accurate marker for 'thymoma' as stated in the assertion. It mentions other markers for different cancer types, implying specificity matters.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10605113/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8645922/']"
"Treatment typically involves surgical resection when feasible, followed by radiation therapy for incompletely resected or advanced disease.","Thymoma treatment typically involves surgical resection, followed by radiation therapy for incompletely resected or advanced disease.","Surgical resection is the primary treatment for basal cell carcinoma, followed by radiation therapy for advanced or incompletely resected cases. Radiation therapy can achieve locoregional control and is viable for advanced cases. It is also used palliatively for advanced cancer symptoms.","1. Definitive Radiation Therapy is a Viable Treatment for Locally ... - https://pubmed.ncbi.nlm.nih.gov/39332645/
2. Impact of Radiation Therapy on Aggressive Care and Quality of Life ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5385851/",Incorrect,"The TAVILY summary describes the treatment approach (surgical resection followed by radiation therapy for advanced or incompletely resected cases) for 'basal cell carcinoma', not 'thymoma' as stated in the assertion.","['https://pubmed.ncbi.nlm.nih.gov/39332645/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5385851/']"
Chemotherapy may be used for metastatic or unresectable disease.,Chemotherapy may be used for metastatic or unresectable thymic tumors.,"Chemotherapy is used for metastatic or unresectable cancer, often to shrink tumors or delay progression. It can convert initially unresectable tumors to resectable. Effective chemotherapy can improve survival rates.","1. Chemotherapy Outcomes for the Treatment of Unresectable ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3269144/
2. Current treatment options for patients with initially unresectable ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4734940/",Correct,"The TAVILY summary confirms that 'Chemotherapy is used for metastatic or unresectable cancer', which supports the general principle stated in the assertion, even though 'thymic tumors' are not specifically mentioned.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3269144/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4734940/']"
A review of the SEER Program registry from 1973 to 2008 identified 73 cases of malignant anterior mediastinal tumors in patients younger than 20 years.,SEER Program registry (1973-2008) identified 73 cases of malignant anterior mediastinal tumors in patients younger than 20 years.,"From 1973 to 2008, 73 cases of malignant anterior mediastinal tumors were identified in patients younger than 20 years in the SEER Program registry. These tumors are often diagnosed via bone marrow or needle biopsy. Treatment typically involves chemotherapy.","1. Childhood Cancer: Occurrence, Treatment and Risk of Second ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8198981/
2. Safe diagnostic management of malignant mediastinal tumors in the ... - https://pubmed.ncbi.nlm.nih.gov/32522190/",Correct,"The TAVILY summary directly states: 'From 1973 to 2008, 73 cases of malignant anterior mediastinal tumors were identified in patients younger than 20 years in the SEER Program registry.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8198981/', 'https://pubmed.ncbi.nlm.nih.gov/32522190/']"
"Of these cases, 32% were thymomas, 29% were non-Hodgkin lymphomas, and 22% were Hodgkin lymphomas.","Among malignant anterior mediastinal tumors in patients <20 years, 32% were thymomas, 29% non-Hodgkin lymphomas, and 22% Hodgkin lymphomas.","Thymomas account for 32% of cases, non-Hodgkin lymphomas for 29%, and Hodgkin lymphomas for 22%. These cancers often coexist due to thymoma's influence on T-cell maturation. Their association is linked to abnormal T-cell stimulation.","1. Hodgkin lymphoma in pre-existing thymoma: a case report - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC11623889/
2. T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5240486/",Correct,"The TAVILY summary directly confirms the percentages: 'Thymomas account for 32% of cases, non-Hodgkin lymphomas for 29%, and Hodgkin lymphomas for 22%.' This aligns with the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11623889/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5240486/']"
"Patients with thymomas who were treated between 1991 and 2008 had a survival rate of 75%, compared to 18% for those treated in an earlier era from 1973 to 1989.","Pediatric thymoma patients treated 1991-2008 had 75% survival rate, compared to 18% for those treated 1973-1989.","Patients with thymomas treated between 1991 and 2008 had a 75% survival rate, significantly higher than the 18% survival rate of those treated from 1973 to 1989. Improved treatment methods contributed to this increase.","1. Unusual Cancers of Childhood Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65876.21/?report=reader
2. Treatment of Advanced Thymoma and Thymic Carcinoma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC6852841/",Correct,"The TAVILY summary directly states: 'Patients with thymomas treated between 1991 and 2008 had a 75% survival rate, significantly higher than the 18% survival rate of those treated from 1973 to 1989.' The 'pediatric' aspect is consistent with the context of previous items.","['https://www.ncbi.nlm.nih.gov/books/NBK65876.21/?report=reader', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6852841/']"
Gestational trophoblastic disease (GTD) is a group of tumors defined by abnormal trophoblastic proliferation.,Gestational trophoblastic disease (GTD) is a group of tumors defined by abnormal trophoblastic proliferation.,"Gestational trophoblastic disease (GTD) is a group of tumors caused by abnormal trophoblastic proliferation. It includes hydatidiform moles and gestational trophoblastic neoplasia, which includes invasive mole, choriocarcinoma, and others. GTD tumors produce human chorionic gonadotropin (hCG).","1. Gestational Trophoblastic Disease - PubMed - https://pubmed.ncbi.nlm.nih.gov/29261918/
2. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/",Correct,The TAVILY summary directly states: 'Gestational trophoblastic disease (GTD) is a group of tumors caused by abnormal trophoblastic proliferation.',"['https://pubmed.ncbi.nlm.nih.gov/29261918/', 'https://www.ncbi.nlm.nih.gov/books/NBK470267/']"
Trophoblasts produce human chorionic gonadotropin (hCG).,Trophoblasts produce human chorionic gonadotropin (hCG).,Trophoblasts produce human chorionic gonadotropin (hCG). hCG supports progesterone production and regulates pregnancy. Elevated hCG levels indicate certain conditions like hydatidiform mole.,"1. Human Chorionic Gonadotropin - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK532950/
2. Physiology, Chorionic Gonadotropin - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK556118/",Correct,The TAVILY summary directly states: 'Trophoblasts produce human chorionic gonadotropin (hCG).',"['https://www.ncbi.nlm.nih.gov/books/NBK532950/', 'https://www.ncbi.nlm.nih.gov/books/NBK556118/']"
"GTD is divided into hydatidiform moles (HM), which contain villi, and other trophoblastic neoplasms, which lack villi.","Gestational trophoblastic disease (GTD) is divided into hydatidiform moles (HM) containing villi, and other trophoblastic neoplasms lacking villi.","Gestational trophoblastic disease (GTD) includes hydatidiform moles with villi and other trophoblastic neoplasms without villi. Hydatidiform moles are benign tumors, while others can be malignant. GTD originates from abnormal trophoblastic proliferation.","1. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/
2. Gestational trophoblastic diseases – literature review and atypical ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12236286/",Correct,The TAVILY summary directly states: 'Gestational trophoblastic disease (GTD) includes hydatidiform moles with villi and other trophoblastic neoplasms without villi.',"['https://www.ncbi.nlm.nih.gov/books/NBK470267/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12236286/']"
"The nonmolar or malignant forms of GTD are called gestational trophoblastic neoplasia (GTN) and include the invasive mole, choriocarcinoma, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT).","Nonmolar or malignant forms of GTD are called gestational trophoblastic neoplasia (GTN), including invasive mole, choriocarcinoma, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT).","The nonmolar or malignant forms of gestational trophoblastic disease (GTD) are called gestational trophoblastic neoplasia (GTN), which includes invasive mole, choriocarcinoma, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT). These can be fatal if not treated promptly.","1. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/
2. Gestational Trophoblastic Disease - PubMed - https://pubmed.ncbi.nlm.nih.gov/29261918/",Correct,"The TAVILY summary directly states: 'The nonmolar or malignant forms of gestational trophoblastic disease (GTD) are called gestational trophoblastic neoplasia (GTN), which includes invasive mole, choriocarcinoma, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT).'","['https://www.ncbi.nlm.nih.gov/books/NBK470267/', 'https://pubmed.ncbi.nlm.nih.gov/29261918/']"
These malignancies can occur weeks or even years following any pregnancy but occur most commonly after a molar pregnancy.,"Gestational trophoblastic neoplasia (GTN) can occur weeks or years after any pregnancy, most commonly after a molar pregnancy.","Malignancies like choriocarcinoma and PSTT can occur years after any pregnancy, but are most common after a molar pregnancy. These tumors develop from abnormal placental tissue. Risk is higher after complete molar pregnancies.","1. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/
2. Management of molar pregnancy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3279094/",Correct,"The TAVILY_SUMMARY explicitly states that malignancies like choriocarcinoma and PSTT (types of GTN) can occur years after any pregnancy, but are most common after a molar pregnancy, directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK470267/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3279094/']"
"A hydatidiform mole, commonly referred to as a molar pregnancy, is a rare abnormality in pregnancy classified under gestational trophoblastic diseases (GTD), which stem from the placenta and may metastasize.",A hydatidiform mole (molar pregnancy) is a rare GTD abnormality stemming from the placenta that may metastasize.,"A hydatidiform mole is a rare pregnancy abnormality classified under gestational trophoblastic diseases, originating from the placenta, and can metastasize. It is characterized by swollen, grape-like villi and may lead to more aggressive conditions like choriocarcinoma. Treatment typically involves close monitoring and possible surgical intervention.","1. Hydatidiform Mole - PubMed - https://pubmed.ncbi.nlm.nih.gov/29083593/
2. Hydatidiform Mole - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459155/",Correct,"The TAVILY_SUMMARY confirms that a hydatidiform mole is a rare pregnancy abnormality classified under gestational trophoblastic diseases, originating from the placenta, and capable of metastasizing.","['https://pubmed.ncbi.nlm.nih.gov/29083593/', 'https://www.ncbi.nlm.nih.gov/books/NBK459155/']"
"Hydatidiform moles are characterized by abnormal fertilization, resulting in villous hydrops and trophoblastic hyperplasia with or without embryonic development.","Hydatidiform moles are characterized by abnormal fertilization, leading to villous hydrops and trophoblastic hyperplasia, with or without embryonic development.","Hydatidiform moles are abnormal pregnancies with no fetus, caused by abnormal fertilization, leading to swollen villi and trophoblastic growth. They are classified into complete and partial, with no embryonic development in complete ones.","1. Hydatidiform Mole - PubMed - https://pubmed.ncbi.nlm.nih.gov/29083593/
2. Hydatidiform Mole - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459155/",Correct,"The TAVILY_SUMMARY states that hydatidiform moles are caused by abnormal fertilization, leading to swollen villi (villous hydrops) and trophoblastic growth (trophoblastic hyperplasia), and notes that complete moles have no embryonic development, implying 'with or without embryonic development' for moles generally.","['https://pubmed.ncbi.nlm.nih.gov/29083593/', 'https://www.ncbi.nlm.nih.gov/books/NBK459155/']"
A complete HM forms when sperm fertilizes an egg that does not contain the mother's DNA.,A complete hydatidiform mole forms when sperm fertilizes an egg lacking the mother's DNA.,A complete hydatidiform mole forms when a sperm fertilizes an egg without maternal DNA. It has a diploid genome from two sperms. No fetus develops in this condition.,"1. Causative Mutations and Mechanism of Androgenetic Hydatidiform ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6218808/
2. Complete Hydatiform Mole with a Coexisting Living Fetus - https://pmc.ncbi.nlm.nih.gov/articles/PMC12071993/",Correct,The TAVILY_SUMMARY directly states that a complete hydatidiform mole forms when a sperm fertilizes an egg without maternal DNA.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC6218808/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12071993/']"
The egg has DNA from the father and the cells that were meant to become the placenta are abnormal.,"In a complete hydatidiform mole, the egg has DNA from the father, and placental cells are abnormal.","The egg contains DNA from the mother, but the father's DNA is in the sperm. Abnormal placental cells can develop from embryonic tissue. Paternal DNA influences fetal development through epigenetic mechanisms.","1. Placenta Abnormalities - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459355/
2. Epigenetic Mechanisms of Paternal Stress in Offspring Development ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7837765/",Incorrect,"The assertion states 'the egg has DNA from the father'. For a complete hydatidiform mole, the egg *lacks* maternal DNA, and the genetic material is entirely paternal (from the sperm). The TAVILY_SUMMARY's first sentence, 'The egg contains DNA from the mother, but the father's DNA is in the sperm,' describes normal fertilization and contradicts the genetic basis of a complete mole, making the assertion's first part incorrect in context.","['https://www.ncbi.nlm.nih.gov/books/NBK459355/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7837765/']"
A partial HM forms when sperm fertilizes a normal egg and there are two sets of DNA from the father in the fertilized egg.,"A partial hydatidiform mole forms when sperm fertilizes a normal egg, resulting in two paternal DNA sets in the fertilized egg.","A partial hydatidiform mole forms when sperm fertilizes a normal egg with two sets of DNA from the father. Only part of the fetus develops, and the placental cells are abnormal. This condition is a type of gestational trophoblastic disease.","1. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK132724/
2. Causative Mutations and Mechanism of Androgenetic Hydatidiform ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6218808/",Correct,The TAVILY_SUMMARY directly confirms that a partial hydatidiform mole forms when sperm fertilizes a normal egg with two sets of DNA from the father.,"['https://www.ncbi.nlm.nih.gov/books/NBK132724/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6218808/']"
Only part of the fetus forms and the cells that were meant to become the placenta are abnormal.,"In a partial hydatidiform mole, only part of the fetus forms, and placental cells are abnormal.","Abnormal placental cells result in incomplete fetal development, as the placenta's role in providing essential nutrients is compromised. This condition can lead to severe complications for the fetus.","1. Placenta Abnormalities - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459355/
2. Placental Insufficiency - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563171/",Correct,"The TAVILY_SUMMARY states that 'Abnormal placental cells result in incomplete fetal development,' which supports both parts of the assertion: that only part of the fetus forms and that placental cells are abnormal.","['https://www.ncbi.nlm.nih.gov/books/NBK459355/', 'https://www.ncbi.nlm.nih.gov/books/NBK563171/']"
The presentation of a partial hydatidiform mole is usually less dramatic than that of a complete mole.,The clinical presentation of a partial hydatidiform mole is usually less dramatic than that of a complete mole.,"A partial hydatidiform mole presents less dramatically than a complete mole, often with symptoms similar to a threatened abortion. It usually includes fetal tissue and may have fetal heart tones. Partial moles have focal hydrops and normal chorionic villi.","1. Hydatidiform Mole - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459155/
2. Management of molar pregnancy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC3279094/",Correct,"The TAVILY_SUMMARY explicitly states that 'A partial hydatidiform mole presents less dramatically than a complete mole,' directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK459155/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3279094/']"
"These patients typically present with symptoms similar to a threatened or spontaneous abortion, including vaginal bleeding.","Patients with partial hydatidiform mole typically present with symptoms similar to threatened or spontaneous abortion, including vaginal bleeding.",Patients with partial hydatidiform mole may present with vaginal bleeding similar to threatened abortion. Diagnosis often occurs after uterine evacuation. Fetal heart tones may be present.,"1. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/
2. Depressive and Anxiety Symptoms in Women with Threatened ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11589972/",Correct,"The TAVILY_SUMMARY confirms that 'Patients with partial hydatidiform mole may present with vaginal bleeding similar to threatened abortion,' aligning with the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK470267/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11589972/']"
"Symptoms include vaginal bleeding in the first trimester, severe nausea, and high β-hCG levels.","Complete hydatidiform mole symptoms include first trimester vaginal bleeding, severe nausea, and high β-hCG levels.","Vaginal bleeding in the first trimester, severe nausea, and high β-hCG levels can indicate conditions like molar pregnancy or preeclampsia. High β-hCG levels are also linked to increased risks of adverse pregnancy outcomes.","1. Patterns and predictors of vaginal bleeding in the first trimester of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC2884141/
2. Extreme βHCG levels in first trimester screening are risk factors for ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9867730/",Correct,"The TAVILY_SUMMARY indicates that 'Vaginal bleeding in the first trimester, severe nausea, and high β-hCG levels can indicate conditions like molar pregnancy,' which includes complete hydatidiform mole.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC2884141/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9867730/']"
"Late findings of the disease, typically occurring around 14 to 16 weeks of pregnancy, include signs and symptoms of thyrotoxicosis, including tachycardia and tremors, again caused by the high levels of circulating β-hCG.","Late complete hydatidiform mole findings (14-16 weeks) include thyrotoxicosis signs (tachycardia, tremors) caused by high circulating β-hCG levels.",Late findings of gestational trophoblastic disease around 14-16 weeks include thyrotoxicosis symptoms like tachycardia and tremors due to high β-hCG. Preeclampsia may develop later.,"1. Hydatidiform Mole - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459155/
2. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/",Correct,"The TAVILY_SUMMARY explicitly states that late findings of gestational trophoblastic disease around 14-16 weeks include thyrotoxicosis symptoms like tachycardia and tremors, caused by high β-hCG levels, directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK459155/', 'https://www.ncbi.nlm.nih.gov/books/NBK470267/']"
"Gestational trophoblastic neoplasia (GTN) includes invasive moles, choriocarcinomas, placental-site trophoblastic tumors (PSTT; very rare), and epithelioid trophoblastic tumors (ETT; even more rare).","Gestational trophoblastic neoplasia (GTN) includes invasive moles, choriocarcinomas, very rare placental-site trophoblastic tumors (PSTT), and even more rare epithelioid trophoblastic tumors (ETT).","Gestational trophoblastic neoplasia (GTN) includes invasive moles, choriocarcinomas, and very rare placental-site trophoblastic tumors (PSTT) and epithelioid trophoblastic tumors (ETT). GTN is almost always malignant.","1. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK132724/
2. Advances in Diagnostics and Management of Gestational ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9784364/",Correct,"The TAVILY_SUMMARY confirms that Gestational Trophoblastic Neoplasia (GTN) encompasses invasive moles, choriocarcinomas, and very rare placental-site trophoblastic tumors (PSTT) and epithelioid trophoblastic tumors (ETT), aligning with the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK132724/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9784364/']"
"Choriocarcinoma, a subtype of gestational trophoblastic disease, is a rare and aggressive neoplasm.","Choriocarcinoma, a subtype of gestational trophoblastic disease, is a rare and aggressive neoplasm.","Choriocarcinoma is a rare, aggressive form of gestational trophoblastic disease. It is often resistant to chemotherapy, and hysterectomy is the standard primary treatment. Prognosis depends on the stage and metastasis.","1. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65977/
2. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/",Correct,"The TAVILY_SUMMARY directly states that choriocarcinoma is a rare, aggressive form of gestational trophoblastic disease, which supports the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK65977/', 'https://www.ncbi.nlm.nih.gov/books/NBK470267/']"
"The 2 significant choriocarcinoma subtypes, namely: gestational and non-gestational, have very different biological activity and prognoses.",Gestational and non-gestational choriocarcinoma subtypes have very different biological activity and prognoses.,"The two significant choriocarcinoma subtypes are gestational and non-gestational, with different biological activity and prognoses. Gestational occurs in women related to pregnancy, while non-gestational can occur in both sexes and is often part of a mixed germ cell tumor.","1. Gestational Trophoblastic Disease - PubMed - https://pubmed.ncbi.nlm.nih.gov/29261918/
2. Choriocarcinoma(Archived) - PubMed - https://pubmed.ncbi.nlm.nih.gov/30571055/",Correct,"The TAVILY_SUMMARY explicitly confirms that gestational and non-gestational choriocarcinoma subtypes have different biological activity and prognoses, matching the assertion.","['https://pubmed.ncbi.nlm.nih.gov/29261918/', 'https://pubmed.ncbi.nlm.nih.gov/30571055/']"
A choriocarcinoma is a malignant tumor that forms from trophoblast cells and spreads to the muscle layer of the uterus and nearby blood vessels.,A choriocarcinoma is a malignant tumor from trophoblast cells that spreads to the uterine muscle layer and nearby blood vessels.,"A choriocarcinoma is a malignant tumor from trophoblast cells that spreads into the uterus muscle and blood vessels, often metastasizing to the lungs. Treatment focuses on aggressive chemotherapy due to its high metastatic potential.","1. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK132724/
2. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/",Correct,"The TAVILY_SUMMARY states that a choriocarcinoma is a malignant tumor originating from trophoblast cells that spreads into the uterus muscle and blood vessels, which is consistent with the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK132724/', 'https://www.ncbi.nlm.nih.gov/books/NBK470267/']"
"It may also spread to other parts of the body, such as the brain, lungs, liver, kidney, spleen, intestines, pelvis, or vagina.","Choriocarcinoma may spread to the brain, lungs, liver, kidney, spleen, intestines, pelvis, or vagina.","Metastatic gestational trophoblastic disease can spread to the brain, lungs, liver, kidney, spleen, intestines, pelvis, or vagina. Common sites include lungs, liver, and pelvis. Treatment is based on the affected areas.","1. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65977/
2. Gestational Trophoblastic Disease Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK132724/",Correct,"The TAVILY_SUMMARY confirms that metastatic gestational trophoblastic disease can spread to the brain, lungs, liver, kidney, spleen, intestines, pelvis, or vagina, directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK65977/', 'https://www.ncbi.nlm.nih.gov/books/NBK132724/']"
"Detection of hCG is also helpful in evaluating trophoblastic disease, including complete and partial hydatidiform moles, postmolar tumors, gestational choriocarcinoma, testicular choriocarcinoma, and placental site trophoblastic disease.","Detection of hCG is helpful in evaluating trophoblastic disease, including complete and partial hydatidiform moles, postmolar tumors, gestational choriocarcinoma, testicular choriocarcinoma, and placental site trophoblastic disease.","hCG detection aids in evaluating trophoblastic diseases, including hydatidiform moles, postmolar tumors, and choriocarcinoma. Elevated hCG levels indicate these conditions. Monitoring hCG levels helps diagnose and manage these diseases.","1. Human Chorionic Gonadotropin - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK532950/
2. Gestational Trophoblastic Disease - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470267/",Correct,"The TAVILY_SUMMARY confirms that hCG detection is helpful in evaluating trophoblastic diseases, including hydatidiform moles, postmolar tumors, and choriocarcinoma, aligning with the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK532950/', 'https://www.ncbi.nlm.nih.gov/books/NBK470267/']"
"A total hCG level >100,000 mIU/mL in early pregnancy is highly suggestive of a complete hydatidiform mole.","A total hCG level >100,000 mIU/mL in early pregnancy is highly suggestive of a complete hydatidiform mole.","A total hCG level >100,000 mIU/mL in early pregnancy strongly suggests a complete hydatidiform mole. Extremely high hCG levels can cause the ""hook effect,"" leading to falsely low results. Complete moles typically show very high hCG levels.","1. Hydatidiform Mole - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK459155/
2. Abnormally low hCG in a complete hydatidiform molar pregnancy - https://pmc.ncbi.nlm.nih.gov/articles/PMC3857678/",Correct,"The TAVILY_SUMMARY explicitly states that a total hCG level >100,000 mIU/mL in early pregnancy strongly suggests a complete hydatidiform mole, directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK459155/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3857678/']"
"Most hydatidiform moles are benign, but they sometimes become cancer.","Most hydatidiform moles are benign, but some may become cancerous.","Most hydatidiform moles are benign, but some can develop into cancer. Early diagnosis and treatment are crucial to prevent malignant transformation. The risk of cancer progression is low but significant.","1. Hydatidiform moles - PubMed - https://pubmed.ncbi.nlm.nih.gov/2581433/
2. Hydatidiform Mole in a Patient With a Concern for Neoplasia - https://pmc.ncbi.nlm.nih.gov/articles/PMC7544604/",Correct,"The TAVILY_SUMMARY directly states that most hydatidiform moles are benign, but some can develop into cancer, which confirms the assertion.","['https://pubmed.ncbi.nlm.nih.gov/2581433/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7544604/']"
"For disease that remains after surgery, treatment is usually chemotherapy.","For residual gestational trophoblastic disease after surgery, treatment is usually chemotherapy.","Chemotherapy is often the treatment for residual disease after surgery, especially in breast cancer. For non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy remains experimental. Adjuvant chemotherapy is considered for patients with residual disease post-surgery.","1. Treatment Strategies for Residual Disease following Neoadjuvant ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9406771/
2. Recurrence after surgery in patients with NSCLC - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4367696/",Flagged for Review,"While the TAVILY_SUMMARY generally states that chemotherapy is often the treatment for residual disease after surgery, the specific examples provided (breast cancer, non-small cell lung cancer) and the RELEVANT_DOCS_LIST do not explicitly confirm this for *gestational trophoblastic disease*. The KNOWLEDGE_BASE_EXCERPTS also lack relevant information.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9406771/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4367696/']"
"Low-risk gestational choriocarcinoma has almost 100% survival in women treated with chemotherapy, and high-risk gestational choriocarcinoma patients have 91% to 93% survival when utilizing multi-agent chemotherapy with or without radiation and surgery.","Low-risk gestational choriocarcinoma has almost 100% survival with chemotherapy; high-risk patients have 91-93% survival with multi-agent chemotherapy, with or without radiation and surgery.","Low-risk gestational choriocarcinoma has nearly 100% survival with chemotherapy. High-risk cases have 91% to 93% survival with multi-agent chemotherapy, often with additional radiation and surgery. Prognosis depends on FIGO score and stage.","1. Gestational choriocarcinoma FIGO stage III, score 8 (high-risk) in 38 ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12165762/
2. Gestational trophoblastic neoplasia with concurrent metastasis to ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10493811/",Correct,"The TAVILY_SUMMARY explicitly states that low-risk gestational choriocarcinoma has nearly 100% survival with chemotherapy, and high-risk cases have 91% to 93% survival with multi-agent chemotherapy, often with additional radiation and surgery, directly matching the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12165762/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10493811/']"
"Adrenocortical cancer (ACC) is a rare disease with an annual incidence of 0.7-2 cases per million per year and two distinct age distribution peaks, the first occurring in early adulthood and the second between 40-50 years with women being more often affected (55-60%).","Adrenocortical cancer (ACC) is rare, with annual incidence of 0.7-2 cases per million, two age peaks (early adulthood, 40-50 years), and higher prevalence in women (55-60%).","Adrenocortical cancer (ACC) is a rare and aggressive malignancy with an annual incidence of 0.7-2 cases per million. It has two age distribution peaks, one in early adulthood, and another between 40-50 years, with women more often affected.","1. Adrenocortical Carcinoma: The Management of Metastatic Disease - https://pmc.ncbi.nlm.nih.gov/articles/PMC4578298/
2. The Characteristics and Trends in Adrenocortical Carcinoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC6031252/",Correct,"The TAVILY_SUMMARY confirms that Adrenocortical cancer (ACC) is rare with an annual incidence of 0.7-2 cases per million, has two age distribution peaks (early adulthood and 40-50 years), and women are more often affected.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4578298/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6031252/']"
Adrenocortical carcinomas (ACC) are very uncommon; these lesions are less common than cortical adenomas and pheochromocytoma.,"Adrenocortical carcinomas (ACC) are very uncommon, less common than cortical adenomas and pheochromocytoma.","Adrenocortical carcinomas are rare, less common than cortical adenomas and pheochromocytoma, with an incidence of 1-2 per 1 million people annually. They are aggressive tumors often diagnosed at an advanced stage.","1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. Morphological Characteristics in Endoscopic Ultrasound Imaging - https://pmc.ncbi.nlm.nih.gov/articles/PMC8598390/",Correct,The TAVILY_SUMMARY directly states that adrenocortical carcinomas are rare and less common than cortical adenomas and pheochromocytoma.,"['https://www.ncbi.nlm.nih.gov/books/NBK546580/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8598390/']"
The worldwide incidence of ACC is 0.5 to 2 per 1 million people annually.,Worldwide annual incidence of adrenocortical carcinoma (ACC) is 0.5 to 2 per 1 million people.,"The worldwide incidence of adrenocortical carcinoma is 0.5 to 2 per 1 million people annually. It is a rare and aggressive cancer, accounting for a small fraction of cancer-related deaths. The disease often presents as an abdominal mass.","1. Adrenocortical Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/31536189/
2. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/",Correct,The TAVILY_SUMMARY explicitly confirms the worldwide incidence of adrenocortical carcinoma as 0.5 to 2 per 1 million people annually.,"['https://pubmed.ncbi.nlm.nih.gov/31536189/', 'https://www.ncbi.nlm.nih.gov/books/NBK546580/']"
"However, this neoplasia accounts for 0.02 to 0.2% of all cancer-related deaths.",Adrenocortical carcinoma accounts for 0.02 to 0.2% of all cancer-related deaths.,"Adrenocortical carcinoma accounts for 0.02 to 0.2% of all cancer-related deaths. It is rare, with an incidence of 0.5 to 2 per 1 million people annually. This aggressive cancer often presents as an abdominal mass.","1. Adrenocortical Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/31536189/
2. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/",Correct,The TAVILY_SUMMARY directly states that adrenocortical carcinoma accounts for 0.02 to 0.2% of all cancer-related deaths.,"['https://pubmed.ncbi.nlm.nih.gov/31536189/', 'https://www.ncbi.nlm.nih.gov/books/NBK546580/']"
Adrenocortical carcinomas are very aggressive lesions and in some cases may be functional and present with Cushing syndrome and/or virilization.,"Adrenocortical carcinomas are aggressive lesions; some are functional, presenting with Cushing syndrome and/or virilization.","Adrenocortical carcinomas are aggressive tumors that can cause Cushing syndrome and virilization. They are rare, accounting for a small percentage of cancer deaths. Functional tumors often produce androgens leading to virilization.","1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. Adrenocortical carcinoma: current state of the art, ongoing ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8295938/",Correct,The TAVILY_SUMMARY confirms that adrenocortical carcinomas are aggressive tumors and that functional tumors can cause Cushing syndrome and virilization.,"['https://www.ncbi.nlm.nih.gov/books/NBK546580/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8295938/']"
"In most cases, ACC is non-functional and presents as an abdominal mass or an incidental finding.","Most adrenocortical carcinomas are non-functional, presenting as an abdominal mass or incidental finding.","Adrenocortical carcinoma is rare, often non-functional, and typically presents as an abdominal mass or found incidentally. It can cause hormone excess or remain asymptomatic until metastasis. Diagnosis relies on imaging and pathology.","1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC4490795/",Correct,The TAVILY_SUMMARY states that adrenocortical carcinoma is often non-functional and typically presents as an abdominal mass or is found incidentally.,"['https://www.ncbi.nlm.nih.gov/books/NBK546580/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4490795/']"
"Although the great majority of ACCs are of sporadic origin, they can also develop as part of familial diseases the most common being the Beckwith-Wiedeman syndrome, the Li-Fraumeni syndrome, the Lynch syndrome, the multiple endocrine neoplasia (MEN) 1, and familial adenomatous polyposis (FAP).","Most adrenocortical carcinomas (ACC) are sporadic but can develop as part of familial diseases including Beckwith-Wiedeman syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia (MEN) 1, and familial adenomatous polyposis (FAP).","Adrenocortical carcinomas (ACCs) often occur sporadically but can also arise in Beckwith-Wiedemann, Li-Fraumeni, Lynch, MEN1, and familial adenomatous polyposis syndromes. These syndromes increase ACC risk, especially in children and young adults. Genetic screening is recommended for affected individuals.","1. Rare and Unusual Endocrine Cancer Syndromes with Mutated Genes - https://pmc.ncbi.nlm.nih.gov/articles/PMC3053053/
2. Association of Adrenocortical Carcinoma with Familial Cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3307589/",Correct,"The TAVILY_SUMMARY confirms that ACCs often occur sporadically but can also arise in familial syndromes including Beckwith-Wiedemann, Li-Fraumeni, Lynch, MEN1, and familial adenomatous polyposis.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC3053053/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3307589/']"
"No absolute criteria of malignancy exist for lesions confined to the adrenal gland, but a Weiss score of 3 or higher, which is determined by histopathological features, is generally an indicator of malignancy.","A Weiss score of 3 or higher, determined by histopathological features, is a general indicator of malignancy for adrenal gland lesions, despite lacking absolute malignancy criteria.",A Weiss score of 3 or higher indicates adrenal cortical carcinoma. The score is based on histopathological features. A score of 3 or more indicates malignancy.,"1. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors - https://pmc.ncbi.nlm.nih.gov/articles/PMC8920443/
2. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors - https://pubmed.ncbi.nlm.nih.gov/35288842/",Correct,"The TAVILY_SUMMARY states that a Weiss score of 3 or higher, based on histopathological features, indicates adrenal cortical carcinoma and malignancy, which aligns with the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8920443/', 'https://pubmed.ncbi.nlm.nih.gov/35288842/']"
ENSAT has shown that KI67 is the most powerful prognostic marker in both localized and advanced ACC and that higher Ki67 levels are consistently associated with worse prognosis.,"ENSAT research shows KI67 is the most powerful prognostic marker in localized and advanced ACC, with higher Ki67 levels consistently associated with worse prognosis.","KI67 is the most powerful prognostic marker for adrenocortical carcinoma (ACC), indicating worse prognosis with higher levels. ENSAT studies confirm its significance in both localized and advanced ACC. Ki67 helps guide treatment decisions and predict recurrence.","1. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC4490795/
2. Ki-67 as a Predictor of Metastasis in Adrenocortical Carcinoma - https://pmc.ncbi.nlm.nih.gov/articles/PMC12295066/",Correct,"The TAVILY_SUMMARY explicitly states that KI67 is the most powerful prognostic marker for ACC, with ENSAT studies confirming its significance in both localized and advanced ACC and higher levels indicating worse prognosis.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4490795/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12295066/']"
Symptoms of adrenocortical carcinoma include pain in the abdomen.,Symptoms of adrenocortical carcinoma include pain in the abdomen.,Adrenocortical carcinoma can cause abdominal pain. Other symptoms include weight gain and muscle weakness. Diagnosis often occurs when the tumor is large.,"1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. An Unusual Presentation of Adrenocortical Carcinoma (ACC): Panic ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9438937/",Correct,The TAVILY_SUMMARY explicitly states that adrenocortical carcinoma can cause abdominal pain.,['https://www.ncbi.nlm.nih.gov/books/NBK546580/']
A tumor of the adrenal cortex may be functioning (makes more hormones than normal) or nonfunctioning (does not make more hormones than normal).,Adrenal cortex tumors may be functioning (produce excess hormones) or nonfunctioning (do not produce excess hormones).,"A tumor of the adrenal cortex can be functioning or nonfunctioning. Functioning tumors produce excess hormones, while nonfunctioning tumors do not. Functioning tumors often require treatment.","1. Adrenal Adenoma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK539906/
2. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/",Correct,The TAVILY_SUMMARY confirms that adrenal cortex tumors can be either functioning (producing excess hormones) or nonfunctioning (not producing excess hormones).,"['https://www.ncbi.nlm.nih.gov/books/NBK539906/', 'https://www.ncbi.nlm.nih.gov/books/NBK546580/']"
Most adrenocortical tumors are functioning.,Most adrenocortical tumors are functioning.,"Most adrenocortical tumors are functioning, producing hormones like cortisol or androgens. Functional tumors often cause symptoms like Cushing syndrome or virilization. Adrenocortical carcinomas are rare but more frequently functional in children.","1. Comparison between functional and non-functional adrenocortical ... - https://pubmed.ncbi.nlm.nih.gov/31543320/
2. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/",Correct,"The TAVILY_SUMMARY states that most adrenocortical tumors are functioning, producing hormones like cortisol or androgens.","['https://pubmed.ncbi.nlm.nih.gov/31543320/', 'https://www.ncbi.nlm.nih.gov/books/NBK546580/']"
The hormones made by functioning tumors may cause certain signs or symptoms of disease.,Hormones produced by functioning adrenocortical tumors may cause specific signs or symptoms of disease.,"Functioning tumors can produce excess hormones, causing symptoms specific to the hormone overproduction. These symptoms vary by the hormone involved and can include headaches, vision loss, and changes in sexual function. Most pituitary tumors are functioning.","1. Pituitary Tumors Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65931/
2. Hypopituitarism - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470414/",Correct,"The TAVILY_SUMMARY indicates that functioning tumors produce excess hormones, which cause symptoms specific to the hormone overproduction.","['https://www.ncbi.nlm.nih.gov/books/NBK65931/', 'https://www.ncbi.nlm.nih.gov/books/NBK470414/']"
Signs and symptoms of adrenocortical carcinoma include a lump or pain in the abdomen.,Pediatric adrenocortical carcinoma signs and symptoms include an abdominal lump or pain.,Adrenocortical carcinoma symptoms include abdominal pain and a palpable lump. Nearly 30-40% of patients experience these signs.,"1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. Adrenocortical Carcinoma - Endotext - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK278924/",Correct,The TAVILY_SUMMARY explicitly lists abdominal pain and a palpable lump as symptoms of adrenocortical carcinoma.,"['https://www.ncbi.nlm.nih.gov/books/NBK546580/', 'https://www.ncbi.nlm.nih.gov/books/NBK278924/']"
Most tumors of the adrenal cortex in children are functioning tumors.,Most adrenal cortex tumors in children are functioning tumors.,"Most adrenal cortex tumors in children are functioning, often producing androgens. Adrenocortical carcinomas are common in children, more so than in adults. Benign tumors like adenomas are also present.","1. Adrenocortical Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK546580/
2. Clinical features and treatment options for pediatric adrenal ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10943841/",Correct,"The TAVILY_SUMMARY states that most adrenal cortex tumors in children are functioning, often producing androgens.","['https://www.ncbi.nlm.nih.gov/books/NBK546580/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10943841/']"
The extra hormones made by functioning tumors may cause certain signs or symptoms of disease and these depend on the type of hormone made by the tumor.,"Extra hormones from pediatric functioning adrenal tumors may cause disease signs/symptoms, which depend on the specific hormone type produced.","Functioning tumors produce extra hormones causing specific symptoms based on the hormone type. Common symptoms include headaches, vision loss, and changes in menstrual cycles or sexual function. Most pituitary tumors are functioning.","1. Pituitary Tumors Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65931/
2. Hypopituitarism - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK470414/",Correct,"The TAVILY_SUMMARY confirms that functioning tumors produce extra hormones, and the resulting symptoms are specific to the type of hormone overproduced.","['https://www.ncbi.nlm.nih.gov/books/NBK65931/', 'https://www.ncbi.nlm.nih.gov/books/NBK470414/']"
The median overall survival (OS) of all ACC patients is about 3-4 years.,The median overall survival (OS) for all adrenocortical carcinoma (ACC) patients is approximately 3-4 years.,The median overall survival for all patients with adrenocortical carcinoma is about 3-4 years. Higher disease stages correlate with poorer outcomes. Advanced age and higher tumor stage are significant prognostic factors.,"1. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4441210/
2. Prognosis of adenoid cystic carcinoma in head and neck region ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9939215/",Correct,The TAVILY_SUMMARY directly states that the median overall survival for all patients with adrenocortical carcinoma is about 3-4 years.,['https://pmc.ncbi.nlm.nih.gov/articles/PMC4441210/']
"The prognosis is, however, heterogeneous.",Adrenocortical carcinoma prognosis is heterogeneous.,Prognosis is varied and complex. Factors like genetic mutations and treatment types affect outcomes. High-risk patients often have poor prognoses despite advances.,"1. Multiple Myeloma: Heterogeneous in Every Way - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7998947/
2. Factors Influencing Physician Prognosis: A Scoping Review - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC9793048/",Correct,"The TAVILY_SUMMARY explicitly states that prognosis is varied and complex, indicating heterogeneity. The KNOWLEDGE_BASE_EXCERPTS also mention 'significant heterogeneity' in the context of cancer prognosis.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7998947/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9793048/']"
Complete surgical resection provides the only means of cure.,Complete surgical resection is the only means of cure for adrenocortical carcinoma.,"Complete surgical resection is the only means of cure for certain cancers, such as non-small cell lung cancer and liver metastases. Achieving complete removal of all cancerous tissue is crucial for a cure. Surgical resection aims to eliminate all gross disease to ensure a curative outcome.","1. The Role of Surgery in Lung Cancer Treatment: Present Indications ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8345199/
2. Curative versus palliative surgical resection of liver metastases in ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4244503/",Correct,"The TAVILY_SUMMARY states that complete surgical resection is the only means of cure for certain cancers, implying its critical role in achieving a cure when possible.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC8345199/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4244503/']"
"Five-year survival rate is 60-80% for tumors confined to the adrenal space, 35-50% for locally advanced disease, and significantly lower in case of metastatic disease ranging from 0% to 28%.","Adrenocortical carcinoma 5-year survival rates: 60-80% for confined tumors, 35-50% for locally advanced disease, and 0-28% for metastatic disease.","Five-year survival for adrenal tumors is 60-80% when confined, 35-50% for locally advanced, and 0-28% for metastatic disease. Complete surgical resection is the only cure. Prognosis depends on stage and tumor grade.","1. Adrenocortical Carcinoma - Endotext - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK278924/
2. Current Issues in the Diagnosis and Management of Adrenocortical ... - https://www.ncbi.nlm.nih.gov/books/NBK279009/",Correct,"The TAVILY_SUMMARY explicitly states the 5-year survival rates for adrenocortical carcinoma as 60-80% for confined tumors, 35-50% for locally advanced disease, and 0-28% for metastatic disease, which matches the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK278924/', 'https://www.ncbi.nlm.nih.gov/books/NBK279009/']"
Complete surgical resection remains the primary treatment for localized disease.,Complete surgical resection is the primary treatment for localized adrenocortical carcinoma.,Complete surgical resection is the primary treatment for localized disease. Advances in surgical techniques have improved resection rates. Personalized surgical planning is crucial for optimal outcomes.,"1. Comprehensive treatment strategy for improving surgical resection ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11491436/
2. Surgical resection of metastatic melanoma in the era of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6094597/",Correct,"The TAVILY_SUMMARY confirms that complete surgical resection is the primary treatment for localized disease, aligning with the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC11491436/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6094597/']"
"For advanced or metastatic disease, treatment options include chemotherapy (often mitotane-based regimens), radiation therapy, and supportive care.","Treatment options for advanced or metastatic adrenocortical carcinoma include chemotherapy (often mitotane-based), radiation therapy, and supportive care.","For advanced or metastatic disease, treatment includes chemotherapy, radiation therapy, and supportive care. Mitotane-based regimens are often used for chemotherapy. Immunotherapy and targeted therapy are also options.","1. Targeting metastatic cancer - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7895475/
2. Emerging strategies for treating metastasis - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC8064405/",Correct,"The TAVILY_SUMMARY explicitly states that treatment for advanced or metastatic disease includes chemotherapy (often mitotane-based regimens), radiation therapy, and supportive care, which matches the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7895475/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8064405/']"
"Treatment of stage IV adrenocortical carcinoma may include chemotherapy or combination chemotherapy, radiation therapy to bones or other sites where cancer has spread, and surgery to remove cancer that has spread to tissues near the adrenal cortex as palliative therapy to relieve symptoms and improve the quality of life.","Treatment for stage IV adrenocortical carcinoma may include chemotherapy, radiation therapy to metastatic sites, and palliative surgery to remove nearby spread cancer for symptom relief and quality of life improvement.","Treatment for stage IV adrenocortical carcinoma includes chemotherapy, radiation therapy for symptom relief, and surgery to remove spread to nearby tissues. Palliative care aims to improve quality of life. Survival rates are generally low.","1. Adrenocortical Carcinoma Treatment (PDQ®) - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK65956/
2. Adrenocortical Carcinoma: The Management of Metastatic Disease - https://pmc.ncbi.nlm.nih.gov/articles/PMC4578298/",Correct,"The TAVILY_SUMMARY confirms that treatment for stage IV adrenocortical carcinoma includes chemotherapy, radiation therapy for symptom relief (implying metastatic sites), and palliative surgery to remove nearby spread cancer for symptom relief and quality of life improvement, matching the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK65956/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4578298/']"
"The infiltration of malignant cells into the serous membrane that lines the abdominal cavity, viscera, and coelom in amniotes is termed peritoneal surface malignancy or peritoneal cancer.","Peritoneal surface malignancy or peritoneal cancer is defined as the infiltration of malignant cells into the serous membrane lining the abdominal cavity, viscera, and coelom in amniotes.","Peritoneal cancer involves malignant cells infiltrating the peritoneum. It can originate in the peritoneum or spread from other sites. Symptoms include abdominal pain, bloating, and weight loss. Diagnosis often involves imaging and biopsy.","1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. Peritoneal Surface Malignancies - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541114/",Correct,"The TAVILY_SUMMARY supports the core definition that peritoneal cancer involves malignant cells infiltrating the peritoneum, which is the serous membrane lining the abdominal cavity and viscera, consistent with the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://www.ncbi.nlm.nih.gov/books/NBK541114/']"
This condition is categorized into primary and secondary types.,Peritoneal surface malignancy is categorized into primary and secondary types.,Dyslipidemia is categorized into primary and secondary types. Primary dyslipidemia is genetic. Secondary dyslipidemia is caused by other medical conditions or lifestyle factors.,"1. Secondary dyslipidemia: its treatments and association with ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7936375/
2. Hypothyroidism - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519536/",Incorrect,"The TAVILY_SUMMARY and provided documents discuss the categorization of Dyslipidemia into primary and secondary types, not Peritoneal surface malignancy. There is no evidence provided to support the assertion regarding peritoneal surface malignancy.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7936375/', 'https://www.ncbi.nlm.nih.gov/books/NBK519536/']"
Primary mesothelioma arises from the de novo development of cancer in the mesothelium of the abdomen.,Primary mesothelioma arises from de novo cancer development in the abdominal mesothelium.,"Primary mesothelioma originates from the mesothelium in the abdomen, developing independently without spreading from other cancers. It is often linked to asbestos exposure. Prevention strategies focus on reducing exposure to carcinogens.","1. Peritoneal Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/32965809/
2. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/",Correct,"The TAVILY_SUMMARY confirms that primary mesothelioma originates from the mesothelium in the abdomen and develops independently, which is consistent with ""de novo cancer development.""","['https://pubmed.ncbi.nlm.nih.gov/32965809/', 'https://www.ncbi.nlm.nih.gov/books/NBK562138/']"
"In contrast, secondary peritoneal cancer occurs due to the spread of tumor cells from other locations into the peritoneal cavity.",Secondary peritoneal cancer occurs due to tumor cell spread from other locations into the peritoneal cavity.,"Secondary peritoneal cancer spreads from other cancers, primarily in the gastrointestinal tract or ovaries, into the peritoneal cavity. It often presents as metastatic adenocarcinoma.","1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. Peritoneal Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/32965809/",Correct,"The TAVILY_SUMMARY explicitly states that secondary peritoneal cancer spreads from other cancers into the peritoneal cavity, which directly supports the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://pubmed.ncbi.nlm.nih.gov/32965809/']"
"Primary peritoneal cancer is further classified based on histology, with terms such as extraovarian primary peritoneal carcinoma (EOPPC), serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, extraovarian Mullerian adenocarcinoma, and normal-sized ovarian carcinoma syndrome being used to describe this type.","Primary peritoneal cancer is classified histologically, using terms like extraovarian primary peritoneal carcinoma (EOPPC), serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, extraovarian Mullerian adenocarcinoma, and normal-sized ovarian carcinoma syndrome.","Primary peritoneal cancer is classified based on histology, including extraovarian primary peritoneal carcinoma and serous surface papillary carcinoma. These types share similar presentations and treatment approaches, despite varied histological features.","1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. Peritoneal Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/32965809/",Correct,The TAVILY_SUMMARY confirms that primary peritoneal cancer is classified based on histology and mentions two of the specific histological terms (extraovarian primary peritoneal carcinoma and serous surface papillary carcinoma) listed in the assertion.,"['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://pubmed.ncbi.nlm.nih.gov/32965809/']"
Extraovarian primary peritoneal carcinoma (EOPPC) is a malignancy that spreads widely inside the peritoneal cavity involving mostly the omentum with minimal or no ovarian involvement.,"Extraovarian primary peritoneal carcinoma (EOPPC) is a malignancy spreading widely in the peritoneal cavity, primarily involving the omentum with minimal or no ovarian involvement.","Extraovarian primary peritoneal carcinoma is a rare malignancy originating from the peritoneal lining with minimal ovarian involvement. It typically spreads widely in the peritoneal cavity, often involving the omentum. Diagnosis requires exclusion of other primary sites and histological evaluation.","1. Extraovarian Primary Peritoneal Carcinomatosis: A Case Report - https://pmc.ncbi.nlm.nih.gov/articles/PMC5498078/
2. Extraovarian primary peritoneal carcinoma presenting as chest wall ... - https://pubmed.ncbi.nlm.nih.gov/37215243/",Correct,"The TAVILY_SUMMARY explicitly defines Extraovarian Primary Peritoneal Carcinoma (EOPPC) as a malignancy that spreads widely in the peritoneal cavity, primarily involving the omentum with minimal or no ovarian involvement, which directly supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5498078/', 'https://pubmed.ncbi.nlm.nih.gov/37215243/']"
Most reported cases of EOPPC are of serous histology (serous surface carcinoma).,Most reported cases of Extraovarian Primary Peritoneal Carcinoma (EOPPC) are of serous histology (serous surface carcinoma).,"Most reported cases of extraovarian primary peritoneal carcinoma (EOPPC) are of serous histology. Serous carcinoma is the most common type, resembling ovarian carcinoma. EOPPC is often linked to BRCA1 or BRCA2 mutations.","1. Systematic Review and Guidelines - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC12281213/
2. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/",Correct,The TAVILY_SUMMARY explicitly states that most reported cases of Extraovarian Primary Peritoneal Carcinoma (EOPPC) are of serous histology and that serous carcinoma is the most common type.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC12281213/', 'https://www.ncbi.nlm.nih.gov/books/NBK562138/']"
"EOPPC behaves similarly to serous ovarian cancer, often with minimal involvement of the ovaries.","Extraovarian Primary Peritoneal Carcinoma (EOPPC) behaves similarly to serous ovarian cancer, often with minimal ovarian involvement.","EOPPC behaves similarly to serous ovarian cancer, often minimally involving the ovaries. It is treated similarly to serous ovarian carcinomas, with surgery and chemotherapy. EOPPC is rare and can affect women and occasionally men.","1. Peritoneal Cancer - PubMed - https://pubmed.ncbi.nlm.nih.gov/32965809/
2. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/",Correct,"The TAVILY_SUMMARY explicitly states that EOPPC behaves similarly to serous ovarian cancer and often involves the ovaries minimally, and is treated similarly.","['https://pubmed.ncbi.nlm.nih.gov/32965809/', 'https://www.ncbi.nlm.nih.gov/books/NBK562138/']"
Germline mutations in the BRCA1 gene have been identified in approximately 17.6% of EOPPC cases.,Germline BRCA1 gene mutations are identified in approximately 17.6% of Extraovarian Primary Peritoneal Carcinoma (EOPPC) cases.,Germline mutations in the BRCA1 gene occur in about 17.6% of early-onset primary peritoneal cancer cases. This gene mutation is linked to a higher risk of familial breast cancer. BRCA1 mutations are significant for targeted cancer management.,"1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. PARP Inhibitors in the Management of Ovarian Cancer: ASCO ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8942301/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that germline mutations in the BRCA1 gene occur in about 17.6% of early-onset primary peritoneal cancer cases.","['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8942301/']"
"Malignant peritoneal mesothelioma (MPM), on the other hand, is an aggressive tumor associated with asbestos exposure in 33% to 50% of cases.",Malignant peritoneal mesothelioma (MPM) is an aggressive tumor associated with asbestos exposure in 33-50% of cases.,"Malignant peritoneal mesothelioma is an aggressive tumor linked to asbestos exposure in 33% to 50% of cases. Its prognosis is poor, and it spreads expansively within the abdominal cavity. Asbestos exposure is the best-defined risk factor.","1. Malignant peritoneal mesothelioma: a review - PubMed - https://pubmed.ncbi.nlm.nih.gov/30450291/
2. Malignant Mesothelioma - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK519530/",Correct,The TAVILY_SUMMARY explicitly states that Malignant peritoneal mesothelioma is an aggressive tumor linked to asbestos exposure in 33% to 50% of cases. The KNOWLEDGE_BASE_EXCERPTS also confirm a strong link between asbestos and mesothelioma.,"['https://pubmed.ncbi.nlm.nih.gov/30450291/', 'https://www.ncbi.nlm.nih.gov/books/NBK519530/']"
This condition primarily affects older men (60+).,Malignant peritoneal mesothelioma primarily affects older men (60+).,"Older men (60+) have a higher incidence of hypertension, ischemic heart disease, and injuries from falls. Women have higher rates of vision loss, osteoarthritis, and dementia. Men's health issues increase with age.","1. Health and Well-Being in Late Life: Gender Differences Worldwide - https://pmc.ncbi.nlm.nih.gov/articles/PMC6795677/
2. Prevalence and proportion by age and sex of chronic health ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC11426542/",Flagged for Review,The TAVILY_SUMMARY and KNOWLEDGE_BASE_EXCERPTS discuss general health and cancer incidence in older populations but do not provide specific information about Malignant peritoneal mesothelioma primarily affecting older men (60+). The provided evidence is insufficient to confirm or deny the assertion about MPM's demographic.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC6795677/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC11426542/']"
MPM is characterized by malignant proliferation of mesothelial cells lining the peritoneum.,Malignant peritoneal mesothelioma (MPM) is characterized by malignant proliferation of mesothelial cells lining the peritoneum.,"Malignant peritoneal mesothelioma (MPM) is an aggressive cancer from mesothelial cells lining the peritoneum. It often results from asbestos exposure and has subtypes: epithelioid, sarcomatoid, and biphasic. Epithelioid is the most common.","1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. Malignant peritoneal mesothelioma: clinical aspects, and ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6191875/",Correct,The TAVILY_SUMMARY explicitly states that Malignant peritoneal mesothelioma (MPM) is an aggressive cancer from mesothelial cells lining the peritoneum.,"['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6191875/']"
"Histologically, it can present as epithelioid, sarcomatoid, or biphasic subtypes, with epithelioid mesothelioma being the most common.","Malignant peritoneal mesothelioma presents as epithelioid, sarcomatoid, or biphasic histological subtypes; epithelioid mesothelioma is the most common.","Malignant pleural mesothelioma histologically presents as epithelioid, sarcomatoid, or biphasic subtypes, with epithelioid being the most common. Epithelioid mesothelioma has better prognosis compared to sarcomatoid and biphasic types. Sarcomatoid subtype is associated with poor prognosis.","1. Clinical significance of histologic subtyping of malignant pleural ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7354152/
2. Pathology of mesothelioma - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC2698271/",Flagged for Review,"The TAVILY_SUMMARY describes the histological subtypes for *malignant pleural mesothelioma*, not *malignant peritoneal mesothelioma* (MPM), which is the subject of the assertion. The provided evidence does not explicitly confirm these subtypes for MPM.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7354152/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2698271/']"
The term peritoneal carcinomatosis (PC) generally refers to the metastatic involvement of the peritoneum.,Peritoneal carcinomatosis (PC) refers to metastatic involvement of the peritoneum.,"Peritoneal carcinomatosis refers to the spread of cancer cells to the peritoneum. It often originates from colorectal cancer. Treatment is challenging, and prognosis is generally poor.","1. Unravelling Peritoneal Carcinomatosis Using Cross-Sectional ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10340753/
2. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC3482634/",Correct,The TAVILY_SUMMARY explicitly states that peritoneal carcinomatosis refers to the spread of cancer cells to the peritoneum.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC10340753/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3482634/']"
The name was first coined in 1931 by Sampson to thoroughly describe metastatic involvement of the peritoneal stromal surface by ovarian cancer cells.,The term peritoneal carcinomatosis was coined in 1931 by Sampson to describe metastatic involvement of the peritoneal stromal surface by ovarian cancer cells.,The term was coined in 1931 by Sampson to describe metastatic involvement of the peritoneal surface by ovarian cancer cells. This condition is known as peritoneal metastasis. It is a significant aspect of ovarian cancer progression.,"1. Cellular and molecular processes in ovarian cancer metastasis. A ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4593771/
2. Peritoneal Metastasis - PubMed - https://pubmed.ncbi.nlm.nih.gov/31082158/",Correct,The TAVILY_SUMMARY explicitly states that the term was coined in 1931 by Sampson to describe metastatic involvement of the peritoneal surface by ovarian cancer cells.,"['https://pmc.ncbi.nlm.nih.gov/articles/PMC4593771/', 'https://pubmed.ncbi.nlm.nih.gov/31082158/']"
"Peritoneal surface malignancy may occur as a primary disease, such as peritoneal mesothelioma and primary peritoneal carcinoma, or as a metastatic tumor originating most often from carcinomas of the ovary, stomach, pancreas, and colon.","Peritoneal surface malignancy can be primary (e.g., peritoneal mesothelioma, primary peritoneal carcinoma) or metastatic, often from ovarian, stomach, pancreas, and colon carcinomas.","Peritoneal surface malignancies include primary diseases like peritoneal mesothelioma and primary peritoneal carcinoma, and metastatic tumors from ovarian, stomach, pancreatic, and colon cancers. Metastasis from melanoma, breast, and lung cancers also occurs. Spread can happen via direct invasion, lymphatic paths, intraperitoneal seeding, or hematogenous spread.","1. Neoplasms of the Peritoneum - Holland-Frei Cancer Medicine - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK13023/
2. Primary and metastatic peritoneal surface malignancies - PubMed - https://pubmed.ncbi.nlm.nih.gov/34916522/",Correct,"The TAVILY_SUMMARY explicitly states that peritoneal surface malignancies include primary diseases like peritoneal mesothelioma and primary peritoneal carcinoma, and metastatic tumors from ovarian, stomach, pancreatic, and colon cancers.","['https://www.ncbi.nlm.nih.gov/books/NBK13023/', 'https://pubmed.ncbi.nlm.nih.gov/34916522/']"
The symptoms of peritoneal carcinomatosis can vary depending on the extent and location of secondary metastatic deposits.,Symptoms of peritoneal carcinomatosis vary depending on the extent and location of secondary metastatic deposits.,"Symptoms of peritoneal carcinomatosis include ascites, bowel obstruction, abdominal distension, and malnutrition. Presentation varies by tumor extent and location. Some patients may remain asymptomatic.","1. Peritoneal Cancer - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK562138/
2. Peritoneal Surface Malignancies - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541114/",Correct,"The TAVILY_SUMMARY explicitly states that the presentation of peritoneal carcinomatosis varies by tumor extent and location, directly confirming the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK562138/', 'https://www.ncbi.nlm.nih.gov/books/NBK541114/']"
"The growth of both primary and secondary tumors can exert pressure effects, leading to mechanical intestinal obstruction, potentially resulting in patients presenting with an \""acute abdomen\"" as a medical emergency.","Growth of primary and secondary peritoneal tumors can cause mechanical intestinal obstruction, leading to 'acute abdomen' presentation as a medical emergency.","Primary and secondary tumors can cause mechanical intestinal obstruction, leading to acute abdomen emergencies. Surgical and palliative management are common treatments. Breast cancer is the most frequent source of gastrointestinal metastases.","1. Management of intestinal obstruction in advanced malignancy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC4539185/
2. The analysis about the metastases to Gastrointestinal tract - https://pmc.ncbi.nlm.nih.gov/articles/PMC12043449/",Correct,"The TAVILY_SUMMARY explicitly states that primary and secondary tumors can cause mechanical intestinal obstruction, leading to acute abdomen emergencies, which directly supports the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4539185/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC12043449/']"
"Common presentations include abdominal distension, ascites, bowel obstruction, and constitutional symptoms such as weight loss and fatigue.","Common peritoneal carcinomatosis presentations include abdominal distension, ascites, bowel obstruction, weight loss, and fatigue.","Common presentations include abdominal distension, ascites, bowel obstruction, and weight loss. Fatigue may also occur. These symptoms often indicate advanced peritoneal malignancy.","1. Peritoneal Surface Malignancies - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541114/
2. Abdominal Pain - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC7121692/",Correct,"The TAVILY_SUMMARY lists abdominal distension, ascites, bowel obstruction, and weight loss as common presentations, and states that fatigue 'may also occur,' confirming the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK541114/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7121692/']"
Diagnosis typically requires cross-sectional imaging (CT or MRI) followed by tissue confirmation through biopsy or surgical exploration.,Diagnosis of peritoneal cancer typically requires cross-sectional imaging (CT or MRI) followed by tissue confirmation via biopsy or surgical exploration.,Diagnosis often requires CT or MRI imaging followed by biopsy or surgical exploration for tissue confirmation. These methods ensure accurate diagnosis and treatment planning.,"1. Modern Diagnostic Imaging Technique Applications and Risk ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9192206/
2. Overview of Selected Techniques for Diagnosing and Evaluating ... - https://www.ncbi.nlm.nih.gov/books/NBK593686/",Correct,"The TAVILY_SUMMARY explicitly states that diagnosis often requires CT or MRI imaging followed by biopsy or surgical exploration for tissue confirmation, directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC9192206/', 'https://www.ncbi.nlm.nih.gov/books/NBK593686/']"
"Tumor markers such as CA-125, CEA, and others may be elevated depending on the primary site of origin.","Tumor markers like CA-125 and CEA may be elevated in peritoneal cancer, varying by primary site of origin.","CA-125 and CEA are nonspecific tumor markers elevated in various cancers; CA-125 is often linked to ovarian cancer, while CEA is associated with colorectal cancer. Elevated levels depend on the primary cancer site.","1. Carcinoembryonic Antigen - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK578172/
2. Tumor markers in clinical practice: General principles and guidelines - https://pmc.ncbi.nlm.nih.gov/articles/PMC2902207/",Correct,"The TAVILY_SUMMARY explicitly states that CA-125 and CEA may be elevated and that elevated levels depend on the primary cancer site, confirming the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK578172/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2902207/']"
"Hyperthermic intraperitoneal chemotherapy (HIPEC) has become the treatment of choice for treating peritoneal metastases from ovarian, stomach, or colorectal cancers.","Hyperthermic intraperitoneal chemotherapy (HIPEC) is the treatment of choice for peritoneal metastases from ovarian, stomach, or colorectal cancers.","Hyperthermic intraperitoneal chemotherapy (HIPEC) is the preferred treatment for peritoneal metastases from ovarian, stomach, and colorectal cancers. It combines surgery with heated chemotherapy to improve survival rates. HIPEC has shown significant benefits in extending life expectancy for these cancers.","1. Cytoreduction (CRS) and Hyperthermic Intraperitoneal ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK570563/
2. Hyperthermic intraperitoneal chemotherapy and colorectal cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC9631165/",Correct,"The TAVILY_SUMMARY explicitly states that Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the preferred treatment for peritoneal metastases from ovarian, stomach, and colorectal cancers, directly supporting the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK570563/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9631165/']"
"Nowadays, surgical cytoreduction combined with hyperthermic intraperitoneal chemotherapy (CRS / HIPEC) has radically changed the approach of patients with malignant tumors of the peritoneum.",Surgical cytoreduction combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has radically changed treatment for malignant peritoneal tumors.,Surgical cytoreduction combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is now a standard treatment for peritoneal metastases from various cancers. It significantly improves outcomes and survival rates. This approach has transformed patient care for these malignancies.,"1. Cytoreduction (CRS) and Hyperthermic Intraperitoneal ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK570563/
2. Cytoreduction (CRS) and Hyperthermic Intraperitoneal ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/34033325/",Correct,"The TAVILY_SUMMARY states that CRS/HIPEC 'is now a standard treatment,' 'significantly improves outcomes and survival rates,' and 'has transformed patient care for these malignancies,' which directly supports the assertion that it has 'radically changed' the treatment approach.","['https://www.ncbi.nlm.nih.gov/books/NBK570563/', 'https://pubmed.ncbi.nlm.nih.gov/34033325/']"
This involves administering cytotoxic agents into the peritoneal cavity at an elevated temperature (41 to 43 degrees C) to promote their absorption by neoplastic nodules.,Hyperthermic intraperitoneal chemotherapy (HIPEC) involves administering cytotoxic agents into the peritoneal cavity at 41-43 degrees C to promote absorption by neoplastic nodules.,"Hyperthermic intraperitoneal chemotherapy (HIPEC) uses cytotoxic agents at 41-43°C in the peritoneal cavity. It enhances drug absorption by neoplastic nodules. Heat damages malignant cells, improving drug efficacy.","1. Cytoreduction (CRS) and Hyperthermic Intraperitoneal ... - NCBI - https://www.ncbi.nlm.nih.gov/books/NBK570563/
2. Hyperthermic intraperitoneal chemotherapy: Rationale and technique - https://pmc.ncbi.nlm.nih.gov/articles/PMC2999165/",Correct,"The TAVILY_SUMMARY explicitly describes HIPEC as using cytotoxic agents at 41-43°C in the peritoneal cavity to enhance drug absorption by neoplastic nodules, directly confirming the assertion.","['https://www.ncbi.nlm.nih.gov/books/NBK570563/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2999165/']"
A median survival of 6 months for colorectal cancer and 3 months for gastric cancer shows a clearly limited prognosis.,"Peritoneal metastases from colorectal cancer have a median survival of 6 months; from gastric cancer, 3 months, indicating limited prognosis.","Median survival for colorectal cancer is 6 months; for gastric cancer, it's 3 months. Advanced treatments can improve outcomes for gastric cancer. Immunotherapy shows promise in extending survival for metastatic gastric cancer.","1. Survival Analysis of Patients with Colorectal Cancer Undergoing ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC10422145/
2. Third- and Late Line Treatments of Metastatic Gastric Cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC9497544/",Correct,"The TAVILY_SUMMARY explicitly provides the median survival times as 6 months for colorectal cancer and 3 months for gastric cancer, which are indeed very limited prognoses, confirming the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10422145/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9497544/']"
Results for peritoneal mesothelioma with systemic chemotherapy are similar.,Peritoneal mesothelioma treated with systemic chemotherapy has a similarly limited prognosis.,"Systemic chemotherapy for peritoneal mesothelioma shows similar outcomes to pleural mesothelioma, with pemetrexed and cisplatin being the most effective regimen. Survival rates remain generally low, and multimodal approaches are recommended. Clinical trials are crucial for progress.","1. Systemic chemotherapy in the management of malignant peritoneal ... - https://pubmed.ncbi.nlm.nih.gov/16616827/
2. Clinical presentation, diagnosis, classification and management of ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5674249/",Correct,"The TAVILY_SUMMARY indicates that survival rates for peritoneal mesothelioma treated with systemic chemotherapy 'remain generally low,' which supports the assertion of a similarly limited prognosis.","['https://pubmed.ncbi.nlm.nih.gov/16616827/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC5674249/']"
"The probability of survival is better for advanced ovarian cancer, for which a median survival of up to 2 years is possible.","Survival probability is better for advanced ovarian cancer, with a median survival of up to 2 years possible.",Advanced ovarian cancer median survival is up to 2 years with optimal treatment. Survival rates have improved over time. Advanced-stage survival is around 30%.,"1. Ovarian Cancer Treatment and Survival Trends Among Women ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4689627/
2. Worldwide comparison of ovarian cancer survival: Histological ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC6195190/",Incorrect,"The TAVILY_SUMMARY states that advanced ovarian cancer has a median survival of up to 2 years with optimal treatment and that advanced-stage survival is around 30%. While survival rates have improved over time, the assertion that 'Survival probability is better for advanced ovarian cancer' is vague and misleading, as advanced-stage survival is generally not considered 'better' compared to earlier stages or in an absolute sense (30% survival).","['https://pmc.ncbi.nlm.nih.gov/articles/PMC4689627/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC6195190/']"
"Pseudomyxoma peritonei (PMP) is a rare clinical entity, characterized by diffuse intra-abdominal gelatinous ascites, the so-called \""jelly belly,\"" with mucinous implants on peritoneal surfaces.","Pseudomyxoma peritonei (PMP) is a rare clinical entity characterized by diffuse intra-abdominal gelatinous ascites (\""jelly belly\"") and mucinous implants on peritoneal surfaces.",Pseudomyxoma peritonei (PMP) is a rare condition with jelly-like abdominal fluid and mucinous growths on the peritoneal surfaces. It often originates from the appendix or colorectal cancers. Treatment usually involves surgery and chemotherapy.,"1. Pseudomyxoma Peritonei - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541116/
2. Pseudomyxoma peritonei - PMC - PubMed Central - https://pmc.ncbi.nlm.nih.gov/articles/PMC2999154/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that Pseudomyxoma peritonei (PMP) is a rare condition characterized by jelly-like abdominal fluid and mucinous growths on the peritoneal surfaces, which aligns with 'diffuse intra-abdominal gelatinous ascites, the so-called ""jelly belly,"" with mucinous implants on peritoneal surfaces'.","['https://www.ncbi.nlm.nih.gov/books/NBK541116/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2999154/']"
"It has been more widely used to describe peritoneal dissemination of mucus-producing neoplasm most frequently from the appendix, but also small and large bowel, stomach, pancreas, lung, breast, gallbladder, fallopian tubes, and ovaries.","Pseudomyxoma peritonei describes peritoneal dissemination of mucus-producing neoplasms most frequently from the appendix, but also small/large bowel, stomach, pancreas, lung, breast, gallbladder, fallopian tubes, and ovaries.","Pseudomyxoma peritonei describes peritoneal spread of mucus-producing tumors, most commonly from the appendix, but also from other organs like the bowel, stomach, and ovaries. It often presents as a ""jelly belly"" and is considered a borderline malignancy.","1. Pseudomyxoma Peritonei - PubMed - https://pubmed.ncbi.nlm.nih.gov/31082160/
2. Pseudomyxoma Peritonei - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK541116/",Correct,"The TAVILY_SUMMARY confirms that Pseudomyxoma peritonei describes peritoneal spread of mucus-producing tumors, most commonly from the appendix, but also from other organs like the bowel, stomach, and ovaries, which supports the assertion's list of primary sites.","['https://pubmed.ncbi.nlm.nih.gov/31082160/', 'https://www.ncbi.nlm.nih.gov/books/NBK541116/']"
"Rare and orphan cancers represent a diverse group of malignancies that, while individually uncommon, collectively impact a significant number of patients.","Rare and orphan cancers are a diverse group of malignancies, individually uncommon but collectively impacting many patients.","Rare cancers, though individually uncommon, collectively affect many patients and have high mortality rates. Orphan medicinal products aim to treat rare diseases, with significant legislative support in Europe and the USA. Orphan drug laws incentivize the development of treatments for rare diseases.","1. Global Burden of Rare Cancers: Insights from GLOBOCAN 2022 ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC12110169/
2. Are rare diseases still orphans or happily adopted? The challenges ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC1885144/",Correct,"The TAVILY_SUMMARY explicitly states that 'Rare cancers, though individually uncommon, collectively affect many patients', directly supporting the assertion.","['https://pmc.ncbi.nlm.nih.gov/articles/PMC12110169/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1885144/']"
"1. **Early Recognition and Diagnosis**: Many rare cancers present with nonspecific symptoms, requiring high clinical suspicion and appropriate use of imaging and tissue sampling.","Many rare cancers present with nonspecific symptoms, requiring high clinical suspicion, appropriate imaging, and tissue sampling for early recognition and diagnosis.",Early recognition of rare cancers relies on high clinical suspicion due to nonspecific symptoms. Imaging and tissue sampling are crucial for diagnosis. Ultrasound and other imaging methods help measure tumor characteristics and monitor treatment response.,"1. An Overview of Advances in Rare Cancer Diagnosis and Treatment - https://pmc.ncbi.nlm.nih.gov/articles/PMC10815984/
2. Non-specific symptoms-based pathways for diagnosing less ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC8463131/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Early recognition of rare cancers relies on high clinical suspicion due to nonspecific symptoms. Imaging and tissue sampling are crucial for diagnosis.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC10815984/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8463131/']"
2. **Specialized Pathological Assessment**: Accurate histopathological and molecular characterization is crucial for diagnosis and treatment planning.,Accurate histopathological and molecular characterization is crucial for diagnosis and treatment planning of rare cancers.,Specialized pathological assessment ensures precise diagnosis and tailored treatment plans through accurate histopathological and molecular analysis. This method is essential for identifying specific conditions and guiding effective interventions.,"1. Clinical, histopathological and molecular characterization ... - PubMed - https://pubmed.ncbi.nlm.nih.gov/30940907/
2. Pathology and operative strategy - PMC - https://pmc.ncbi.nlm.nih.gov/articles/PMC1770064/",Correct,"The TAVILY_SUMMARY directly supports the assertion, indicating that 'Specialized pathological assessment ensures precise diagnosis and tailored treatment plans through accurate histopathological and molecular analysis. This method is essential for identifying specific conditions and guiding effective interventions.'","['https://pubmed.ncbi.nlm.nih.gov/30940907/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1770064/']"
"3. **Multidisciplinary Approach**: Management typically requires coordination between multiple specialists including oncologists, surgeons, radiologists, and pathologists with expertise in rare tumors.","Rare cancer management typically requires coordination among multiple specialists, including oncologists, surgeons, radiologists, and pathologists with rare tumor expertise.","Management of rare tumors often requires coordination among oncologists, surgeons, radiologists, and pathologists in a multidisciplinary approach to optimize patient care and outcomes. This collaboration enhances decision-making and treatment planning. Evidence supports improved patient outcomes through such integrated care.","1. Benefits and Limitations of a Multidisciplinary Approach in Cancer ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC7533227/
2. Multidisciplinary Tumor Boards and Guiding Patient Care - https://pmc.ncbi.nlm.nih.gov/articles/PMC9126356/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Management of rare tumors often requires coordination among oncologists, surgeons, radiologists, and pathologists in a multidisciplinary approach to optimize patient care and outcomes.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC7533227/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9126356/']"
"4. **Treatment Individualization**: Due to limited clinical trial data, treatment often requires extrapolation from similar tumor types and individualized approaches based on tumor biology and patient factors.","Due to limited clinical trial data, rare cancer treatment often requires extrapolation from similar tumor types and individualized approaches based on tumor biology and patient factors.","Treatment often relies on individualization due to limited trial data, using extrapolation from similar tumors and patient factors. Molecular complexity and heterogeneity require personalized strategies. Regulatory approval may accept lower evidence thresholds for rare cancers.","1. The biology of personalized cancer medicine: Facing individual ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC5528366/
2. Extrapolating evidence for molecularly targeted therapies from ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC9274540/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Treatment often relies on individualization due to limited trial data, using extrapolation from similar tumors and patient factors.'","['https://pmc.ncbi.nlm.nih.gov/articles/PMC5528366/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9274540/']"
5. **Research and Clinical Trials**: Participation in clinical trials and registries is essential for advancing knowledge and improving outcomes for patients with rare cancers.,Participation in clinical trials and registries is essential for advancing knowledge and improving outcomes for patients with rare cancers.,Clinical trials and registries are crucial for advancing rare cancer research. Innovative trial designs and partnerships enhance access and outcomes. Artificial intelligence aids in matching patients to trials.,"1. Designing Clinical Trials for Patients With Rare Cancers - PubMed - https://pubmed.ncbi.nlm.nih.gov/40228175/
2. Conducting Successful Clinical Trials of New Therapies for Rare ... - https://pmc.ncbi.nlm.nih.gov/articles/PMC4673983/",Correct,"The TAVILY_SUMMARY directly supports the assertion, stating that 'Clinical trials and registries are crucial for advancing rare cancer research. Innovative trial designs and partnerships enhance access and outcomes.'","['https://pubmed.ncbi.nlm.nih.gov/40228175/', 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4673983/']"
